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Abstract 
Emerging viral diseases cause significant and widespread economic losses to U.S. swine 
production.  Over the last 25 years, porcine reproductive and respiratory syndrome virus 
(PRRSV), porcine circovirus type 2 (PCV2) and porcine epidemic diarrhea virus (PEDV) have 
emerged or re-emerged, costing the industry billions through increased mortality and clinical or 
subclinical reductions in growth.  Nursery pigs are greatly affected by these viruses due to high 
susceptibility to primary and secondary infections after weaning.  However, clinical disease 
occurs in only a subpopulation of infected pigs and can vary drastically from sudden death to 
poor growth performance.  This thesis documents a series of 4 studies where nursery pigs were 
challenged with either PRRSV/PCV2 or PEDV; the associations between clinical outcome and 
several factors affecting viral pathogenesis were investigated.   
In the first study, the administration of PRRS modified live virus vaccine prior to co-
challenge with PRRSV/PCV2 was shown to protect against PRRS but enhance PCV2 replication 
and pathogenesis.  This study provides insight into the role that PRRS vaccination has in both the 
control and potentiation of clinical disease.  In the second study, microbial populations were 
compared between pigs with the best and worst clinical outcome following PRRSV/PCV2 co-
infection.  Increased fecal microbiome diversity was associated with improved clinical outcome; 
however, worst clinical outcome pigs had prolonged and greater virus replication, highlighting 
the host response to viral challenge as a primary determinant of clinical outcome.  In the third 
study, 13 clinical phenotypes were compiled for >450 pigs after PRRSV/PCV2 co-infection.  
Duration of dyspnea and the presence of muscle wasting had the strongest associations with 
reduced weight gain.  This study highlights the opportunity to improve animal welfare and 
production through improvements in clinical health.  In the fourth study, clinical disease was 
  
mild to moderate and occurred within the first week after pigs were challenged with PEDV.  
However, PEDV was detected weeks after clinical disease had resolved and may implicate 
nursery pigs as an important source of viral carriage and transmission.  Overall, the goal of this 
thesis was to develop models for understanding the impact of emerging and re-emerging viruses 
to improve recognition and control of disease. 
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Chapter 1 - Vaccination with a porcine reproductive and 
respiratory syndrome (PRRS) modified live virus vaccine 
followed by challenge with PRRSV and porcine circovirus 
type 2 (PCV2) protects against PRRS but enhances PCV2 
replication and pathogenesis when compared to non-
vaccinated co-challenged controls 
 Abstract 
Co-infections involving porcine reproductive and respiratory syndrome virus (PRRSV) 
and porcine circovirus type 2 (PCV2) contribute to a group of disease syndromes known as 
porcine circovirus associated disease (PCVAD).  Presumably, PRRSV infection enhances PCV2 
replication as a result of modulation of host immunity.  The purpose of this study was to evaluate 
PCV2 replication and pathogenesis in pigs vaccinated with a PRRS modified live virus (MLV) 
vaccine and subsequently challenged with a combination of PRRSV and PCV2.  During the early 
post-challenge period, PRRSV-associated clinical signs were decreased and average daily gain 
(ADG) was increased in the vaccinated group, demonstrating the protective effect of PRRS 
vaccination.  However, during the later post-challenge period, the vaccinated group showed 
greater numbers of pigs with increased PCV2 viremia, decreased ADG, increased PCVAD 
clinical signs, and increased mortality.  In this disease model, the early benefits of PRRSV 
vaccination were outweighed by the later amplification of PCVAD.  
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 Introduction 
Porcine circovirus type 2 (PCV2), a single-stranded DNA virus in the family 
Circoviridae, contributes to a group of syndromes collectively termed porcine circovirus 
associated disease (PCVAD) (Baekbo et al., 2012).  Two important clinical syndromes 
associated with PCVAD include PCV2-associated pneumonia and postweaning multisystemic 
wasting syndrome (PMWS) (Baekbo et al., 2012; Ramamoorthy and Meng, 2009).  Management 
of PCV2 through the use of inactivated and subunit vaccines have led to the effective control of 
PCVAD in North America and Europe.  However, the emergence of new PCV2 strains and the 
lack of PCV2 vaccination programs in other countries create an uncertain future for continued 
disease control.   
Porcine reproductive and respiratory syndrome virus (PRRSV) is a single-stranded RNA 
virus in the family Arteriveridae (Benfield et al., 1992; Conzelmann et al., 1993).  For the past 
20 years, PRRSV has remained the most costly disease affecting swine production worldwide 
(Chand et al., 2012).  PRRSV infection contributes to a number of immunological outcomes that 
increase the susceptibility of the host to secondary infections by primary and secondary 
pathogens (Gomez-Laguna et al., 2013; Opriessnig et al., 2011; Renukaradhya et al., 2010).  
PRRSV is frequently isolated along with PCV2 (Pallares et al., 2002) and is one of the major co-
factors linked with increasing PCV2 replication and pathogenesis (Allan et al., 2000a; Harms et 
al., 2001; Rovira et al., 2002).  Previous work by us and others has shown that a principal 
contribution of PRRSV is to increase PCV2 viremia (Trible et al., 2012a).  Increased PCV2 
replication is likely the result of immune stimulation that results in more PCV2-permissive cells 
combined with PRRSV-induced immunomodulation.  The complex etiology of PCVAD, 
including the role of PRRSV infection, has yet to be fully understood.  In an extensive body of 
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work, we identified the aberrant recognition of a non-neutralizing decoy epitope on the PCV2 
capsid protein (CP) as a contributing factor to PCVAD immunopathogenesis.  Natural PCV2 
infection of a population produces a mixture of pigs that recognize the decoy and neutralizing 
epitopes, which may explain why only a subpopulation of infected pigs go on to develop 
PCVAD (Trible et al., 2011; Trible et al., 2012a; Trible et al., 2012b).   
In this study, we took advantage of a host genetics study to evaluate clinical and 
virological outcomes after experimental challenge with PCV2 and PRRSV in pigs with and 
without prior vaccination with a commercial PRRS MLV.  The results demonstrate the protective 
properties of vaccination; however, the short-term benefit is outweighed by the longer term 
impact of MLV on PCVAD. 
 
 Materials and Methods 
Animals and housing.  Experiments involving animals and viruses were performed in 
accordance with the Federation of Animal Science Societies (FASS) Guide for the Care and Use 
of Agricultural Animals in Research and Teaching, the USDA Animal Welfare Act and Animal 
Welfare Regulations, and approved by the Kansas State University Institutional Animal Care and 
Use Committees and Institutional Biosafety Committees.  The study was conducted as part of the 
evaluation of a previously described genomic marker, WUR (Boddicker et al., 2012).  The 
population of pigs used in this study was composed of two genotypes, 50% WUR genotype AA 
and 50% AB or BB.  The AB and BB genotypes were predicted to have a beneficial effect in 
response to PRRSV infection.  Both vaccine and non-vaccine groups were balanced according to 
WUR genotype; therefore, WUR was not a factor when comparing the outcomes of vaccine and 
non-vaccine groups.  Three week-old barrows (n = 226; average age of 19.4 ± 1.8 days) were 
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obtained from a high-health commercial source negative for PRRSV.  While pigs were derived 
from a sow herd previously vaccinated with a PCV2 capsid subunit vaccine, the piglets were not 
vaccinated for PCV2, and were obtained after weaning without regards to maternal antibody 
levels.  All pigs were housed in two environmentally controlled rooms at the Kansas State 
University Large Animal Research Center, and maintained under BSL-2 conditions.  Rooms 
were chemically disinfected, cleaned with a high heat pressure washer and gas decontaminated 
with vaporized hydrogen peroxide prior to use.  Both rooms were empty for at least 19 days prior 
to the start of the study.  Pigs were housed in 20 pens, each 144 sq ft with 11-12 pigs per pen.  
Pigs were given access to food and water ad libitum.         
Experimental Design. A total of 226 pigs were randomly allocated into two identical 
rooms using a random number assignment protocol and housed in groups of 11-12 pigs per pen.  
After acclimating for four days, one room of 115 pigs was vaccinated with a 2 ml dose of 
commercial PRRS MLV vaccine (Ingelvac PRRS MLV, Boehringer Ingelheim Animal Health; 
GenBank Accession #AF159149) administered intramuscularly according to the vaccine label 
instructions.  At 28 days post-vaccination (dpv), all pigs in both rooms were challenged with a 
combination of PRRSV and PCV2b.  Individual body weights were collected on -3, 0, 7, 14, 21, 
28, 35, 42, 49, 56, 63, and 70 dpv.  Blood samples were collected from all pigs on 0, 4, 7, 11, 14, 
21, 28, 35, and 42 days post-infection (dpi).  Blood was also collected from the vaccinated group 
on 0, 4, 7, 11, 14, and 21 dpv.  At 11 dpi, 10 vaccinated and 10 non-vaccinated pigs were 
randomly selected for humane euthanasia and complete necropsies were performed.  Between 32 
and 42 dpi, 11 pigs showing clinical signs of PCVAD and 7 nonclinical pigs were humanely 
euthanized and complete necropsies were performed.  These pigs were selected based on clinical 
disease without regards to vaccine status.     
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Challenge inoculum. The PRRSV and PCV2b isolates used to prepare the inoculum 
were originally derived from the lymph node of a pig with severe PMWS, as described 
previously (Trible et al., 2011; Trible et al., 2012a).  PRRSV (isolate KS62, GenBank Accession 
#KM035803) was isolated by propagation on MARC-145 cells.  The PRRSV component of the 
challenge inoculum, KS62, shared 88.06% identity with the MLV (GenBank Accession 
#AF159149) at the peptide sequence level of GP5.  Since wild-type PCV2b (Genbank Accession 
#JQ692110) does not propagate to high levels in cell culture, we took advantage of the heat 
stability of PCV2 to make a virus preparation from a lymph node suspension enriched for PCV2.  
The suspension was heat-treated at 55
o
 C for 30 minutes to remove PRRSV, bacteria and other 
heat-labile agents.  The treated homogenate was recombined with the isolated PRRSV to infect 
cesarean-derived, colostrum-deprived (CD/CD) pigs.  A combination lung/lymph node 
homogenate was prepared from the CD/CD pigs and PRRSV and PCV2 were isolated from the 
homogenate by the methods described above.  Analysis of the heat-treated preparation for 
common agents showed that the preparation was negative for most heat stable agents, such as 
parvovirus, but still positive for torque teno sus virus (TTSuV) and porcine oncovirus (PCOV), 
which are ubiquitous.   
PRRSV was tittered on MARC-145 cells.  Briefly, virus was serially diluted 1:10 in 
MEM (Corning) supplemented with 7% FBS (Sigma-Aldrich), Pen Strep (80 Units/ml and 80 
μg/ml, respectively; Gibco), 3 ug/ml Fungizone (Gibco), and 25 mM HEPES (Life 
Technologies).  The dilutions were then added in quadruplicate to confluent MARC-145 cells in 
a 96 well tissue culture plate (BD Falcon).  Following a 4 day incubation at 37
o
C in 5% CO2, 
wells were examined for PRRSV induced cytopathic effects, and the 50% tissue culture 
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infectious dose (TCID50/ml) was calculated using the method of Reed and Muench (Reed and 
Muench, 1938). 
The quantity of PCV2 was determined by titration on swine testicle (ST) cells.  Briefly, 
serial 10-fold dilutions of the PCV2 challenge stock were plated in quadruplicate to rapidly 
dividing ST cells in a 96 well tissue culture plate (BD Falcon).  Dilutions were prepared in 
EMEM (Sigma-Aldrich) supplemented with 7% FBS (Sigma-Aldrich) and 50 μg/ml of 
gentamycin (Lonza).  Following a three day incubation at 37
o
C in 5% CO2, cells were fixed and 
permeabilized with 80% acetone and then stained with fluorescein isothiocyanate (FITC)-labeled 
porcine anti-PCV (Veterinary Medical Research and Development, Inc.).  Infected cells were 
visualized using an inverted fluorescent microscope and the TCID50/ml was calculated using the 
method of Reed and Muench (Reed and Muench, 1938). 
The challenge viruses were recombined to yield a 2 ml dose consisting of 10
3.6
 TCID50 
PCV2 and 10
5
 TCID50 PRRSV in MEM.  The 2 ml dose was split with 1 ml administered 
intranasally and the remaining 1 ml administered intramuscularly.   
Clinical Evaluation. Pigs were evaluated daily for the presence of clinical signs 
associated with PCVAD, including dyspnea, aural cyanosis, coughing, nasal discharge, open 
mouth breathing, poor body condition, muscle wasting, pallor or jaundice, lameness, joint 
effusion, depression and lethargy.  Each pig was visually examined by a veterinarian or 
veterinary assistant each day during the study period.  Appropriate treatments were initiated for 
pigs that presented with moderate to severe clinical disease.  Examples of clinical presentations 
where treatment was administered included: 1. Difficult respiration, 2. Mucoid nasal discharge, 
3. Lameness with associated joint effusion, 4. Pallor or jaundice associated with muscle wasting, 
and 5. Lethargy or depression with rectal temperature ≥104°F.  For clinically affected pigs, 
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antibiotic therapy was administered, including ceftiofur hydrochloride for respiratory or systemic 
disease, oxytetracycline for infectious arthritis, and enrofloxacin for cases unresponsive to the 
previous two antibiotics.  All pigs with overt clinical disease and rectal temperatures ≥104°F 
were administered flunixin meglumine, a nonsteroidal anti-inflammatory drug (NSAID).  Pigs 
with intractable fevers of greater than 4 days duration were given a 2 day wash-out period and 
then administered oral meloxicam.  All treatments were administered as directed by a 
veterinarian.  Clinical signs and systemic treatments unrelated to PRRSV or PCVAD (e.g. 
lacerations, dermatitis, hoof wounds, congenital hernias) were documented but were not included 
in the data analysis related to clinical outcomes.  Animals were humanely euthanized with 
pentobarbital sodium.  Pigs that died or were humanely euthanized due to circumstances 
unrelated to the effects of co-infection were excluded from the mortality analysis.  Average daily 
gain (ADG) was calculated as the change in weight divided by the number of days and was 
reported as kg per day. 
Gross pathology and histopathology.  Lungs were removed in toto immediately after 
euthanasia.  The scoring of gross lung lesions was performed using two techniques.  First, the 
percentage of lung affected by pneumonia was estimated for both the dorsal and ventral aspects 
of each lung lobe during gross necropsy.  Results were reported as the percentage of whole lung 
affected by pneumonia (ranging from 0 to 100%) (Halbur et al., 1995).  Second, dorsal and 
ventral aspects of the whole lung were photographed (Olympus Stylus 7010 camera) and digital 
images were evaluated after gross necropsy using a photo scoring system.  Gross anatomical 
photo scores were determined on a scale of 0 to 4: 0 = no macroscopic lesions; 1 = pneumonia 
affecting < 25% of gross lung; 2 = pneumonia affecting 25-50% of gross lung; 3 = pneumonia 
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affecting 50-75% of gross lung; and 4 = pneumonia affecting > 75% of gross lung.  The 
evaluator was blind as to the source of the lung pictures. 
For histopathology, tissues collected from lung, tracheobronchial lymph node and 
inguinal lymph node were immediately placed in 10% neutral buffered formalin and allowed to 
fix for at least 7 days.  Fixed tissues were processed in an automated tissue processor and 
embedded in paraffin.  Slide-mounted tissue sections were stained with hematoxylin and eosin 
(H&E stain) and evaluated by a blinded board-certified pathologist.  Microscopic lung lesions 
were estimated based on the following scoring system: 0 = no significant microscopic lesions; 1 
= mild interstitial pneumonia with <50% lung lobe involvement; 2 = mild to moderate multifocal 
interstitial pneumonia with 50-75% lung lobe involvement; 3 = moderate to severe multifocal 
interstitial pneumonia with 50-75% lung lobe involvement; 4 = severe diffuse interstitial 
pneumonia with >75% lung lobe involvement.  The final scores assigned to each pig was an 
average from two separate evaluations by the same pathologist, who remained blinded to the 
source of the lung tissue.    
PCV2 immunohistochemical staining. PCV2 antigen staining in paraffin-embedded 
tissue thin sections was performed by personnel in the Kansas State Veterinary Diagnostic 
Laboratory.  Briefly, deparaffinized slide-mounted thin sections were first treated with proteinase 
K (1.2 mg/ml diluted in Bond Enzyme Diluent with 0.35% ProClin 950) for 10 minutes at room 
temperature (Bond Enzyme Pretreatment Kit, Leica Biosystems).  Rabbit anti-PCV2 antibody 
(Iowa State University) was diluted at 1:500 in Bond Primary Antibody Diluent (Leica 
Biosystems) and applied to the tissue section for 15 minutes at room temperature.  Bound 
antibody was detected by incubation with 25 μg/ml Poly-AP anti-rabbit IgG (Leica Biosystems) 
in antibody diluent for 25 minutes at room temperature.  The complex was visualized using Fast 
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Red chromogen (Bond Polymer Refine Red Detection Kit, Leica Biosystems) and counterstained 
with hematoxylin. 
Measurement of PRRSV and PCV2 viremia. Viral DNA and RNA were extracted 
simultaneously from 50 μL of serum using Ambion’s MagMAX 96 Viral Isolation Kit (Applied 
Biosystems) in accordance to the manufacturer’s instructions.  PRRS viral RNA was quantified 
using EZ-PRRSV MPX 4.0 Real Time RT-PCR Target-Specific Reagents (Tetracore) according 
to the manufacturer’s instructions.  For consistency, each plate contained Tetracore 
Quantification Standards and Control Sets for use with EZ-PRRSV MPX 4.0 RT-PCR Reagents.  
All PCR reactions were carried out on a CFX96 Touch Real-Time PCR Detection System (Bio-
Rad) in a 96-well format using the recommended cycling parameters.  PCV2 DNA was 
quantified using SsoAdvanced Universal SYBR Green Supermix (Bio-Rad).  Forward and 
reverse PCR primers were 5’-AATGCAGAGGCGTGATTGGA-3’ and 5’-
CCAGTATGTGGTTTCCGGGT-3’, respectively.  Primers were used at a final concentration of 
300 μM.  Nuclease free water was used to bring the mastermix volume to 18 μL per reaction.  
The addition of 2 μL of template nucleic acid brought the final reaction volume for each sample 
to 20 μL.  Standard curves and positive and negative controls were included on each plate.  
Plasmid DNA was used for the PCV2 standard curve and positive control template.  DNA 
inserted into the plasmid was obtained from a field strain of PCV2 (PCV2b 321/393).  Plasmid 
DNA was isolated using the PureYield Plasmid Miniprep System (Promega) according to the 
manufacturer’s instructions.  The DNA for the standard curve was quantified using a NanoDrop 
8000 Spectrophotometer.  The standard curve was produced by diluting the purified plasmid 
DNA 1:1000 in nuclease free water followed by five serial 1:10 dilutions in nuclease free water.  
The final standard curve contained 6 points ranging from 10
7
 to 10
2
 logs of template DNA which 
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produced threshold crossing values between 15 and 33 cycles.  Standard curves were run in 
duplicate with nuclease free water as a negative control.  The PCV2 PCR was carried out on a 
CFX96 Touch Real-Time PCR Detection System using the following settings: activation at 98°C 
for 2 minutes, followed by 40 cycles of denaturing at 98°C for 5 seconds and 
annealing/extension at 60°C for 10 seconds.  The melting curve was performed between 65-95°C 
using 0.5°C increments.  The PCR assay results were reported as log10 PRRSV RNA starting 
quantity (copy number) per 50 μL reaction volume or log10 PCV2 DNA starting quantity per 20 
μL reaction volume. 
Microsphere immunoassay for detection of PCV2 antibodies. A PCV2b capsid 
protein (CP) polypeptide fragments CP(43-233) and CP(160-233) were cloned and expressed in 
the E.coli vector, pHUE, as previously described (Trible et al., 2011).  For protein expression, 
bacteria were grown in Luria-Bertani (LB) broth plus ampicillin (0.01 mg/ml) and incubated at 
37
o
C with shaking.  When the OD
600
 reached 0.4-0.6, protein expression was induced with 
isopropyl β-D-1-thiogalactopyranoside (IPTG; 1 mM/ml final concentration) and bacteria 
harvested 4 hours later.  Protein was purified using the USB PrepEase Histidine-tagged Protein 
Purification Kit (Affymetrix) under non-denaturing conditions, according to the manufacturer’s 
directions.  Purity was assessed by SDS-PAGE and total protein measured using the Bio-Rad 
Protein Assay.  
Proteins were coupled to carboxylated Luminex MagPlex
®
 polystyrene microspheres 
according to the manufacturer’s directions.  For the assay, approximately 2500 antigen-coated 
beads, suspended in 50 μL PBS with 10% goat serum (PBS-GS), were placed in each well of a 
96-well polystyrene round bottom plate (Costar).  Sera were diluted 1:400 in PBS-GS and 50 μL 
was added to each well.  The plate was wrapped in foil and incubated for 30 min at room 
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temperature with gentle shaking.  The plate was placed on a magnet and beads were washed 
three times with 190 µL of PBS-GS.  For the detection of IgG, 50 µL of biotin-SP-conjugated 
affinity purified goat anti-swine secondary antibody (IgG, Jackson ImmunoResearch) was 
diluted to 2 µg/mL in PBS-GS and 100 μl was added to each well.  The plate was incubated at 
room temperature for 30 min and washed three times followed by the addition of 50 µL of 
streptavidin-conjugated phycoerythrin (2 ug/ml in PBS-GS; SAPE).  After 30 min, the plate was 
washed and microspheres resuspended in 100 µL of PBS-GS.  Microspheres were analyzed 
using a MAGPIX instrument (Luminex) and Luminex
®
 xPONENT 4.2 software.  A minimum of 
100 microspheres was used for the calculation of mean fluorescence intensity (MFI).  The 
sample to positive (S/P) ratio was calculated as the MFI of sample minus MFI of negative 
control divided by MFI of standard positive control minus MFI of negative control. 
Statistical analyses. A logistic mixed model was used to evaluate the effect of 
vaccination on the binary traits of blue ear, veterinary treatment for PCVAD, and mortality.  The 
model included the design effects of vaccination, WUR, the interaction between vaccination and 
WUR, and initial body weight as a covariate.  Random effects included sire, dam and pen.  Odds 
ratios for the effect of vaccination were estimated as the vaccinated group over the non-
vaccinated group (treatment and mortality) and the non-vaccinated group over the vaccinated 
group (blue ear).  Odds ratios included Wald’s confidence intervals (CI). 
Data on percent lung lobe involvement was analyzed as a normal quantitative response 
variable, whereas gross anatomical photo scores and microscopic lung lesion scores were 
analyzed as ordinal categorical variables in a mixed multinomial regression.  The model included 
the fixed effects of PRRS vaccination, WUR, their interaction, and clinical signs 
(presence/absence).  Sire and dam were included as random effects.  All analyses were 
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performed using the GLIMMIX procedure of SAS 9.3 (Statistical Analysis System Institute, 
Inc.).  Average daily gain, viremia, and antibody response comparisons between groups were 
performed using GraphPad Prism 5.00 software using the unpaired t-test.   
 
 Results 
PRRSV viremia is decreased after PRRS vaccination but PCV2 viremia is 
increased. PRRS MLV replication in the vaccine group prior to challenge was assessed by RT-
PCR on serum samples collected at 11 dpv.  The results showed that 78 of the 84 pig sera tested 
(or 93%) possessed detectable levels of vaccine virus, confirming that the pigs supported active 
MLV replication (Figure 1).  Mean viremia at 11 dpv was 2.7 ± 1.7 log10 templates per PCR 
reaction.  Prior to challenge, the non-vaccine group was negative for PRRSV nucleic acid in 
serum (data not shown).   
  The results for PRRSV and PCV2 viremia after challenge are shown in Figure 2.  
PRRSV infection in the non-vaccine group followed the typical course of viremia, peaking 
between 7 and 11 dpi, followed by a decay and eventual disappearance of virus from the blood 
by 42 dpi.  In the vaccine group, 90% of pigs (102/113) possessed detectable levels of virus 
nucleic acid in serum at 28 days after vaccination or at the time of challenge.  The PRRSV 
viremia in the vaccine group peaked at about seven days after challenge and then decayed.  
Except for the day of challenge and day 42, the mean PRRSV level was significantly lower on all 
days in the vaccine group (see Figure 1A).  Compared to the non-vaccinated pigs, peak viremia 
at days 7 and 11 for the vaccine group was reduced by more than one log.  The results 
demonstrated that vaccination was effective in reducing PRRS viremia in a heterologous 
challenge model.   
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Mean PCV2 viremia for vaccine and non-vaccine groups is presented in Figure 2B.  In 
the non-vaccine group, mean PCV2 viremia peaked at about 21 days after challenge and 
remained elevated for the remainder of the study.  In contrast, mean PCV2 viremia for the 
vaccine group peaked at 14 dpi when the mean virus level was approximately 1.5 logs greater for 
the vaccine group compared to the non-vaccine group (p < 0.0001).  Thus, PCV2 viremia in the 
vaccine group peaked much earlier.   
PCV2 immunization of dams provides temporary protection of piglets from PCV2 
infection.  However, by 35 days after weaning, passive immunity decays to the point that pigs 
become susceptible to PCV2, a virus that is normally present in the environment.  At the time of 
challenge, low but detectable levels of PCV2 nucleic acid were present in 7 of 115 vaccinated 
pigs (6%) and 25 of 111 non-vaccinated pigs (22%).  Mean PCV2 viremia prior to challenge was 
2.3 and 2.9 log10 templates per PCR reaction for PCR-positive vaccine and non-vaccine pigs, 
respectively.  The increased proportion of non-vaccinated pigs with evidence of PCV2 exposure 
prior to challenge may account for the differences in the outcomes for the two groups.  However, 
the exclusion of these 32 pigs did not alter the conclusions of the study.   
PRRS vaccination results in reduced clinical signs and pathology during the first 21 
days after co-infection.  Prior to virus challenge, clinical signs were not apparent in either the 
vaccinated or the non-vaccine group.  After infection, two clinical syndromes emerged.  The first 
was a PRRSV-associated syndrome, aural cyanosis, commonly known as “blue ear” (Done and 
Paton, 1995; Paton et al., 1991), which was easily identified in pigs by the presence of red, 
cyanotic, or blue discoloration of the ear tissue.  Even though blue ear is not pathognomonic for 
PRRS, it often coincides with acute infection.  A representative example of a pig with “blue ear” 
is shown in Figure 3.  No “blue ear” was observed prior to challenge in either the vaccinated or 
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the non-vaccinated pigs.  However, during the post-challenge period, 64 of the 226 pigs or 
28.3% of all pigs were documented as having blue ear on one or more days.  As shown in Figure 
4A, the percentage of pigs with blue ear peaked between 8 and 17 dpi, which corresponded to the 
peak in PRRSV viremia (compare Figure 2A).  Overall, 19% of vaccinated pigs (22/115) and 
38% of non-vaccinated pigs (42/111) were documented with blue ear.  A non-vaccinated pig was 
3.02 times (95% CI [1.7, 5.9]) more likely to develop blue ear than a vaccinated pig (p = 0.001).  
The total number of days with blue ear was 65 and 201 for the vaccine and non-vaccine groups, 
respectively.  The reduction in the number of pigs with blue ear in the vaccine group is consistent 
with a beneficial effect of the PRRS MLV.  
The primary clinical sign associated with acute PRRSV infection is respiratory disease 
resulting from interstitial pneumonia.  Lungs were removed from 20 euthanized pigs (10 pigs 
from each group), which were randomly selected at 11 dpi.  Figure 5 shows a summary of the 
gross and microscopic lung scores.  Mean scores for the percent gross lung lobe involvement and 
microscopic scoring for interstitial pneumonia were higher in the non-vaccine group; however, 
the differences were not statistically significant (p = 0.62 for percent lung involvement and p = 
0.30 for histopathology score).  Together, the results showed that PRRS vaccination with MLV 
had an overall protective effect by reducing PRRSV viremia and decreasing PRRS-associated 
clinical signs.  
PRRS vaccination results in increased clinical signs and pathology at 22-42 days 
after co-infection. Beyond the acute period of infection, a second clinical syndrome appeared, 
which first became apparent by an increase in the number of pigs receiving systemic veterinary 
treatment due to clinical signs associated which PCVAD, such as tachypnea, dyspnea, pyrexia, 
loss of condition, muscle wasting, mucoid nasal discharge, lethargy, and pallor or jaundice (see 
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Figure 4B).  Lesions typical of PCVAD were found by gross anatomical and microscopic 
examinations of lung and lymph nodes from pigs that died or were euthanized.  Representative 
pictures and photomicrographs showing the lesions associated with clinically affected pigs are 
presented in Figure 6.  Lungs showed multifocal to diffuse interstitial pneumonia with mottling 
of lung tissue, hemorrhage, and consolidation (Figure 6A).  At the microscopic level, multifocal 
to diffuse interstitial pneumonia with lymphohistiocytic infiltration into the alveolar septa and 
peribronchiolar areas was easily visible (see Figure 6B).  Lymph nodes of affected pigs showed 
depletion of lymphocytes (see Figure 6C).  Positive staining for PCV2 antigen was observed in 
lymph nodes and lungs of affected pigs (see Figure 6D).  The analysis of gross and microscopic 
lesions combined with the accumulation of PCV2 antigen in target organs confirmed the 
presence of PCVAD.  The number of pigs undergoing treatment as a result of PCVAD-
associated clinical signs peaked between 22 and 35 dpi (see Figure 4B).  During this time, there 
were 39 pigs that received at least 1 day of veterinary treatment, including 12 non-vaccinated 
pigs (12/101; 12%) versus 27 pigs in the vaccine group (27/105; 26%).  A vaccinated pig was 
2.67 times (95% CI [1.23, 5.80]) more likely to receive veterinary treatment during peak 
PCVAD than a non-vaccinated pig (p = 0.01).  High amounts of PCV2 in serum were associated 
with the 39 pigs that went on to develop PCVAD.  At 14 dpi, significantly higher levels of 
circulating PCV2 were present in the 39 PCVAD pigs (mean = 5.8 log10 templates/PCR reaction) 
compared to the 163 nonclinical pigs (mean = 4.8 log10 templates/PCR reaction; p = 0.004).  
Different treatments administered to the 39 clinical pigs included a single antibiotic and a 
NSAID (16/39; 41%), multiple antibiotics and a NSAID (7/39; 18%), a single antibiotic (6/39; 
15%), multiple antibiotics (3/39; 8%), and a NSAID alone (3/39; 8%).  Four of the 39 pigs (10%) 
were humanely euthanized after the initial treatment due to the severity of the clinical 
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presentations.  The decline in the percentage of pigs with PCVAD clinical signs was largely the 
result of increased mortality or the euthanization of pigs that were moribund or nonresponsive to 
treatment (compare Figures 4B and C).  Over the entire study period, there were 49 pigs that 
received at least 1 day of systemic veterinary treatment; 16% in the non-vaccine group (18/111) 
versus 27% in the vaccine group (31/115).  A vaccinated pig was 1.79 times (90% CI [0.99, 
3.25]) more likely to receive veterinary treatment during the entire study period than a non-
vaccinated pig (p = 0.11). 
 Macroscopic and microscopic changes in organs and tissues were evaluated between 32 
and 42 dpi in 11 clinically affected pigs, which were humanely euthanized as a result of failure to 
respond to treatment.  For the purpose of comparison, 7 nonclinical pigs were also necropsied.  
As summarized in Table 1, all 11 clinical pigs showed some form of macroscopic lung 
involvement, as determined by the photographic score.  The macroscopic scores for the 
nonclinical group were significantly lower (p = 0.04).  A similar trend between clinically 
affected and non-affected pigs appeared at the microscopic level; however, the difference was 
not statistically significant (p = 0.16).  Mild to severe lymphoid depletion was observed in 8 of 
the 11 clinical pigs (73%) compared to only 3 of the 7 (43%) nonclinical pigs.  Even though the 
nonclinical pigs appeared normal, almost all showed some form of pathology related to PCVAD, 
such as mild to moderate pneumonia and/or mild lymphoid depletion. 
The effect of PRRS MLV vaccination on mortality. As illustrated in Figure 4C, of the 
101 non-vaccinated pigs, 9 died, resulting in an overall survival rate of 91.1%.  Of the 105 
vaccinated pigs, 14 died, for an overall survival rate of 86.7% (see Figure 4C).  A vaccinated pig 
was 1.7 times (95% CI [0.89, 3.72]) more likely to die during the overall study period than a 
non-vaccinated pig (p = 0.35).  Increased mortality became apparent after 20 days and was 
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associated with the appearance of PCVAD.  Of the 39 pigs that developed clinical signs of 
PCVAD, 21 died prior to the end of the study (14 vaccinated and 7 non-vaccinated), resulting in 
a mortality rate of approximately 54% in pigs exhibiting clinical signs.  Between 22 and 35 dpi, a 
vaccinated pig was 2.1 times (90% CI [1.03, 5.87]) more likely to die than a non-vaccinated pig 
(p = 0.09).  Even though mortality was higher in the vaccine group, the differences between 
vaccine and no vaccine groups were not significantly different.  
Vaccination increases the appearance of antibodies against a PCV2 decoy epitope. In 
previous work we identified the presence of antibodies against a decoy epitope in the capsid 
protein of PCV2, CP(160-180), correlated with PCVAD.  The presence of an anti-CP(160-180) 
response is associated with the absence of PCV2 neutralizing activity in serum.  Pigs vaccinated 
for PCV2 and protected from disease produce little anti-CP(160-180) activity and preferentially 
recognize a larger epitope, CP(43-233).  Pigs that are naturally infected with PCV2 show a 
mixture of the two antibody responses.  As a means to standardize results across plates, the anti-
PCV2 antibody response for the vaccine and non-vaccine groups was presented as a CP(160-
233)/CP(43-233) ratio.  The higher the ratio, the more the immune response is skewed towards 
the recognition of the decoy epitope.  The results, presented in Figure 7, showed a significant (p 
= 0.0006) difference in the CP(160-233)/CP(43-233) mean ratios; 0.85 for the non-vaccinated 
pigs versus 0.97 for the vaccinated group.  The exclusion of the 32 pigs which showed the 
presence of PCV2 nucleic acid at the time of challenge changed the ratios, but did not affect the 
conclusion; CP(160-233)/CP(43-233) mean ratios of 0.92 for the non-vaccinated pigs (n = 61) 
and 0.98 for the vaccinated group (n = 72; p = 0.03).       
As discussed above, previous work showed that pigs with low CP(160-233)/CP(43-233) 
ratios are protected from disease.  Therefore, non-vaccinated pigs with ratios less than 0.5 (n = 
18 
13) were compared to non-vaccinated pigs with PCV2 antibody ratios greater than 0.5 (n = 68).  
Pigs with antibody ratios of less than 0.5 had significantly lower levels of circulating PCV2 in 
the serum on 21 (p = 0.0001), 28 (p = 0.0008), 35 (p = 0.007), and 42 (p = 0.03) dpi compared to 
the pigs with the higher ratios.  The results confirm earlier findings describing the non-protective 
effect of anti-CP(160-233) antibodies.  
The effect of PRRS MLV vaccination on average daily gain. Over the entire 70 day 
study period, the mean average daily gain (ADG) for the vaccine group (n = 91) was 0.65 ± 0.11 
kg compared to 0.68 ± 0.10 kg for the no vaccine pigs (n = 92).  The means between the two 
groups were significantly different (p = 0.029).  Decreased mean ADG was also observed in the 
vaccine group during the 42 day post-virus challenge period.  However, the difference between 
the vaccine (0.82 ± 0.14 kg, n = 91) and no vaccine (0.86 ± 0.14 kg, n = 92) groups was not 
statistically significant (p = 0.061).  In addition, ADG differences between the two groups were 
no longer significant during the 70 day study period after excluding the 32 pigs with PCV2 
detected prior to challenge.   
Therefore, a more detailed analysis was conducted by calculating ADG on a weekly basis 
(see Figure 8).  The results showed that ADG differences between no vaccine and vaccine groups 
could be divided into three distinct phases.  The first phase, covering the pre-challenge period, 
showed that mean ADG after vaccination was reduced, with a significant difference between 
vaccinated and non-vaccinated groups appearing at three weeks after vaccination.  The second 
phase covered the period during acute PRRSV infection.  At one week after virus challenge, 
mean ADG was significantly increased for the vaccine group.  ADG remained higher in the 
second week post-challenge, but the difference was not significant.  Improved ADG in 
vaccinated pigs was likely the result of the positive effect of vaccination on reducing PRRS-
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associated clinical signs and virus load (see Figures 2A and 4A).  The third phase covered the 
period from the onset of PCVAD, beginning at about three weeks after virus challenge, until the 
end of the study.  During this phase, ADG was lower in the vaccinated group at every time point, 
with significantly lower mean ADG values on week six after virus challenge.  A significant 
decrease in ADG was also initially detected for vaccinated pigs on week three post-challenge; 
however, this difference was no longer significant after the 32 PCV2 positive pigs had been 
excluded (p = 0.08).  The lower mean ADG values are consistent with the effect of PCVAD, 
characterized by poor growth performance and muscle wasting.    
The negative effect of vaccination on ADG could have been the result of increased 
numbers of pigs with clinically apparent PCVAD.  Therefore, a separate analysis was performed 
after the 26 clinical pigs that survived the length of the study had been excluded from the vaccine 
and no vaccine groups.  Removing clinical pigs increased ADG of the two groups; 0.69 ± 0.09 
kg in nonclinical non-vaccinated pigs (n = 83) and 0.66 ± 0.10 kg in nonclinical vaccinated pigs 
(n = 74; p = 0.047).  However, even in the absence of overt clinical signs, PRRS vaccination 
possessed a negative effect on weight gain.      
 
 Discussion 
Enhanced PCV2 infection leading to PCVAD is typically associated with immune 
stimulation (Krakowka et al., 2001; Opriessnig and Halbur, 2012).  PCV2 replication is located 
in the nucleus of permissive cells and is dependent on cellular enzymes expressed during the S 
phase of the cell cycle (Tischer et al., 1987).  It is presumed that actively dividing lymphocytes, 
in response to an immune stimulus, provide the cellular environment ideal for supporting PCV2 
replication.  PRRSV, porcine parvovirus and Mycoplasma hyopneumoniae are common co-
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pathogens linked with lymphoproliferation and increased PCV2 pathogenesis (Allan et al., 1999; 
Allan et al., 2000a; Ellis et al., 1999; Fan et al., 2013; Harms et al., 2001; Kennedy et al., 2000; 
Krakowka et al., 2000; Opriessnig et al., 2004; Rovira et al., 2002; Sinha et al., 2011; Trible et 
al., 2012a).  Examples of non-infectious immunostimulators include immunization with keyhole 
limpet hemocyanin in incomplete Freund’s adjuvant (Krakowka et al., 2007; Krakowka et al., 
2001) and inactivated vaccines, such as Mycoplasma hyopneumoniae (Allan et al., 2000b; 
Krakowka et al., 2007; Opriessnig et al., 2003) and Actinobacillus pleuropneumoniae (Allan et 
al., 2000b; Opriessnig et al., 2003).  The results from this study showed that PRRS MLV initially 
had a beneficial effect in reducing PRRS-associated clinical signs and PRRS viremia; however, 
PRRS-vaccinated pigs showed increased PCV2 replication, reduced average daily gain and 
increased clinical signs associated with PCVAD.   
Previous experimental studies documenting interactions between PRRS MLV and PCV2 
infection have yielded conflicting results.  Allan et al. (Allan et al., 2007) found that colostrum-
deprived, specific-pathogen-free (SPF) pigs infected with PCV2 at five weeks of age and 
administered PRRS MLV one week later had greater amounts of PCV2 antigen in tissues and 
more severe histologic lesions, characteristic of PMWS, compared to pigs infected with PCV2 
alone.  However, pigs failed to exhibit clinical signs or gross lesions typical of PCVAD (Allan et 
al., 2007).  In contrast, Opriessnig et al. (Opriessnig et al., 2006) evaluated the effects of PCV2 
infection on the efficacy of PRRS MLV in groups of 10 early weaned SPF pigs.  Pigs were 
inoculated with PCV2 at six weeks of age, vaccinated with PRRS MLV two weeks later, and 
then challenged with PRRSV at twelve weeks of age.  The results showed that the group with 
PCV2 and MLV exhibited lower ADG and more severe lung lesions after PRRSV challenge 
compared to those pigs that were vaccinated and received PRRSV challenge without PCV2.  
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Because PCV2 was not detected by IHC in affected lungs, the authors attributed the lesions to 
PRRSV infection and further concluded that the effect of PCV2 was to reduce the efficacy of 
PRRS MLV (Opriessnig et al., 2006).  Park et al. (Park et al., 2013) investigated the potential for 
PRRS MLV to reduce PRRSV-associated amplification of PCV2 pathogenesis after co-infection 
with PRRSV and PCV2.  Groups of 8 conventional pigs were subjected to a variety of treatments 
involving different combinations of PRRS MLV, wild-type PRRSV, PCV2 vaccine, and PCV2.  
Pigs were vaccinated with PRRS MLV, PCV2 subunit vaccine or both and then four weeks later, 
challenged with PRRSV, PCV2 or both.  The group that received PRRS MLV followed by co-
infection showed no differences in PCV2 viremia, PCV2 associated pathology, or the number of 
PCV2-positive cells in lymph node and lung when compared to the co-infected group that was 
not vaccinated with PRRS MLV (Park et al., 2013).  In contrast to our study in which 
vaccination enhanced PCVAD, these authors found that co-infected pigs, with or without 
previous PRRS MLV vaccination, had similar PCV2 replication and pathogenesis.  
Field studies have also yielded conflicting results.  A survey conducted on 70 pig farms 
in the Netherlands included questions regarding PRRS MLV use on farms with and without 
PMWS or PCVAD.  Results showed that PRRS MLV is a significant risk factor for PMWS 
outbreaks (De Jong et al., 2003).  In contrast, an analysis of the effect of PRRS MLV on farms 
affected by PCVAD in the U.S. found that farms incorporating PRRS MLV have significantly 
lower PCV2 viremia compared to non-vaccinated farms during peak wasting disease (Genzow et 
al., 2009).  In this study, qPCR was used to measure PCV2 in serum samples collected at 
different time points from 6 herds using PRRS MLV and 12 non-vaccinated herds.  These results 
suggest that PRRS MLV can reduce PCV2 viremia (Genzow et al., 2009). 
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The failure of experimental studies to find a consistent link between PRRS MLV and 
PCVAD was likely in part due to the length of the observation period.  For example, the studies 
described above were terminated on 25 dpi with PCV2 (Allan et al., 2007) and 21 days after 
challenge with PRRSV/PCV2 (Park et al., 2013).  In the current study, peak PCVAD occurred 
between 22-35 days after challenge with PRRSV/PCV2.  Another important difference is the size 
of the experimental groups.  Typically, the prevalence of clinically ill pigs on farms affected by 
PCVAD is only 2-25% (Kyriakis et al., 2002; Quintana et al., 2001; Sorden et al., 1998).  Pigs 
with clinical disease may not be apparent or present in small groups of pigs.  The current study 
utilized over 200 pigs, mimicking the environment found in the field and providing the depth of 
data to observe and quantify low-percentage outcomes.  PCVAD morbidity was 11.9% and 
25.7% in non-vaccinated and vaccinated pigs, respectively.  Therefore, PCVAD should be 
assessed by comparing mortality rates, clinical disease presentation, viremia, and weight gain in 
relatively large groups evaluated for several weeks after infection.   
Because large groups of pigs were required to ensure clinical disease expression, some 
control groups, including pigs challenged with PCV2 or PRRSV alone, were not incorporated 
into the study design.  Therefore, conclusions are based on vaccinated and non-vaccinated co-
challenged pigs and generalizing results to single infections (i.e. PRRS MLV effect on PCV2 
challenged pigs) should be considered with caution. 
PCV2 is ubiquitous in swine populations and elimination of the virus from the 
environment is extremely difficult.  As demonstrated in this study, 32 of 226 pigs had detectable 
PCV2 in the serum at the time of challenge.  Although these pigs were the minority (14%) and 
group titers were relatively low (2.3 and 2.9 log10 templates per PCR reaction), the presence of 
PCV2 prior to challenge had to be considered as a possible factor in post-challenge response.  
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This was especially true due to the difference between proportions of PCV2-positive pigs in each 
group, despite randomized allocation of pigs and balanced genotypes.  This difference was likely 
due to the failure of randomization to equally distribute PCV2-positive pigs across the two 
groups.  Therefore, analyses were also completed after the 32 pigs were excluded and all 
conclusions of the study were confirmed.  Regardless, this highlights the difficulty in eliminating 
PCV2 from the environment and further, suggests that pigs should be balanced according to 
PCV2 status prior to challenge.                   
Significantly increased PCV2 viremia in PRRS MLV treated pigs was observed at 11 and 
14 days after challenge, but not at later time points (see Figure 2B).  This effect of PRRS MLV 
on PCV2 infection is similar to that seen in a previous study by us, which showed a significant 
increase in PCV2 viremia at 23 days after co-infection with PRRSV and PCV2 (Trible et al., 
2012a).  In the current study, it is interesting to note that PCV2 viremia levels were not 
significantly different between the vaccine and no vaccine groups during peak PCVAD.  
However, the 39 clinical pigs did maintain significantly higher levels of circulating PCV2 during 
these later time points (21 and 35 dpi, p < 0.02, data not shown).  Increased incidence of PCVAD 
in vaccinated pigs between 22-35 dpi may also be the result of greater levels of localized PCV2 
in tissues.  Future studies are needed to assess differences in quantity and tissue distribution of 
PCV2 between vaccinated and non-vaccinated pigs.     
Average daily gain (ADG) is used in swine production as an objective measure of overall 
health and performance.  The negative effect of PRRS MLV on growth performance is well 
documented.  For example, Opriessnig et al. reported that pigs vaccinated with PRRS MLV at 
two weeks of age exhibited a significant reduction in ADG compared to non-vaccinated pigs 
(Opriessnig et al., 2005).  Pretzer et al. found that PRRS MLV vaccinated weaned pigs had lower 
24 
ADG between 0-14 dpv compared to non-vaccinated pigs (Pretzer et al., 1996).  While this effect 
on ADG was no longer apparent between 21 and 42 dpv, the vaccinated pigs maintained lighter 
weights overall (Pretzer et al., 1996).  We confirmed the negative effect of PRRS MLV on ADG 
during the 28 day period prior to co-infection; significantly reduced ADG was observed during 
the third week after vaccination (see Figure 8).  The benefit of PRRS vaccination was 
documented during the first two weeks after PCV2/PRRSV challenge, when MLV had a positive 
effect on ADG.  Although vaccinated pigs in this study had increased ADG in the first two 
weeks post-challenge, this effect was quickly outweighed when ADG was decreased in the 
presence of PCVAD.  Vaccination decreased ADG in both clinically-affected and nonclinical 
pigs during the study period, demonstrating that poor growth performance may be a subclinical 
manifestation of PCVAD in apparently healthy pigs.   
At least three mechanisms may be involved in the enhancement of PCVAD following 
PRRS vaccination.  PRRS MLV may function to stimulate the immune system and increase the 
number of PCV2 permissive cells.  Similar to wild-type viruses, lymphocytes undergo mitosis in 
response to vaccination with PRRS MLV, thereby increasing the population of cells with the 
ability to support PCV2 replication.  In addition, the vaccine likely stimulates PRRSV-specific 
lymphocyte populations that are re-stimulated after challenge with a wild-type PRRSV.  
Secondly, similar to wild-type PRRS viruses, PRRS MLV may suppress innate immunity, 
thereby blocking anti-PCV2 responses.  For example, PRRSV non-structural proteins, such as 
nsp1 and nsp2, block the induction and response of cells to interferon (Chand et al., 2012).  Viral 
proteins, such as nsp1α and nsp1β, antagonize the type I interferon response by degrading key 
components needed for interferon gene expression and inhibiting interferon signaling pathways 
(Chen et al., 2010; Han and Yoo, 2014).  And finally, the third mechanism is based on the 
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possibility that PRRS MLV may skew the immune response towards the production of non-
neutralizing PCV2-specific antibodies. 
PCV2 has circulated in the swine population for at least 25 years.  In 2005, the 
emergence of PCV2b in North America was attributed to outbreaks of PCVAD (Carman et al., 
2008; Cheung et al., 2007; Horlen et al., 2007).  Since then, the disease has been effectively 
managed through the use of PCV2 vaccines (Horlen et al., 2008; Kixmoller et al., 2008; 
Velasova et al., 2013).  Therefore, the negative effect of MLV on PCV2 infection may not be 
relevant.  However, there remain several countries in which PRRS MLV vaccination is in wide 
use, but in the absence of a comprehensive PCVAD vaccination program.  Further, there is the 
potential for new and emerging PCV2 strains to escape current vaccine protection.  Emerging 
PCV2 mutant strains have been documented in China (Guo et al., 2010) and more recently were 
associated with PCVAD outbreaks in vaccinated herds in the U.S. and Korea (Opriessnig et al., 
2013; Seo et al., 2014).  Overall, this study supports the notion that maintaining a successful 
PCV2 control program and assessing the risk of virulent PRRSV exposure is critical to weighing 
the benefits of PRRS MLV.   
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Table 1:1 Lung and lymph node lesions of pigs with clinical signs associated with PCVAD 
and nonclinical pigs between 32 and 42 dpi
a
 
Macroscopic Lung Lesion Score
b
* 0 1 2 3 4  
Clinical Pigs  0 (0) 4 (36) 2 (18) 1 (9) 4 (36)  
Nonclinical Pigs 1 (14) 4 (57) 1 (14) 1 (14) 0 (0) 
Microscopic Lung Lesion Score
c
 0 1 2 3 4  
Clinical Pigs 0 (0) 1 (9) 3 (27) 7 (64) 0 (0)  
Nonclinical Pigs 0 (0) 1 (14) 4 (57) 2 (29) 0 (0)  
Amount of Lymphoid Depletion
d
  None Mild Moderate Severe   
 Clinical Pigs 3 (27) 4 (36) 2 (18) 2 (18)   
Nonclinical Pigs 4 (57) 3 (43) 0 (0) 0 (0)   
a
 18 pigs were necropsied including pigs showing clinical signs associated with PCVAD (n = 11) and 
apparently healthy pigs (n = 7). Data are shown as the number and percentage of pigs in parentheses. 
b
 Scores were determined by evaluation of ventral and dorsal photographs of lungs: 0 = no macroscopic 
lesions; 1 = pneumonia affecting < 25% of gross lung; 2 = pneumonia affecting 25-50% of gross lung; 
3 = pneumonia affecting 50-75% of gross lung; and 4 = pneumonia affecting > 75% of gross lung. 
c
 Scores were determined by evaluation of tissue sections stained with hematoxylin and eosin: 0 = no 
significant microscopic lesions; 1 = mild interstitial pneumonia with <50% lung lobe involvement; 2 = 
mild to moderate multifocal interstitial pneumonia with 50-75% lung lobe involvement; 3 = moderate 
to severe multifocal interstitial pneumonia with 50-75% lung lobe involvement; 4 = severe diffuse 
interstitial pneumonia with >75% lung lobe involvement. 
d
 Amount of lymphoid depletion was determined by evaluation of lymph node and tonsil tissue sections 
stained with hematoxylin and eosin: Mild = small amount of lymphocyte depletion with replacement 
by histiocytes; Moderate = intermediate amount of lymphocyte depletion with replacement by 
histiocytes; Severe = large amount of lymphocyte depletion with replacement by histiocytes.  
* Data for Clinical versus Nonclinical pigs was statistically different (p = 0.0426), based on ordinal 
logistic regression. 
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Figure 1:1 Distribution of viremia at 11 days after vaccination with PRRS MLV. 
The figure represents PRRSV RT-PCR results for 84 pigs in the vaccine group. 
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Figure 1:2 PRRSV and PCV2 viremia in vaccinated and non-vaccinated pigs. 
The figure shows PCR values as mean ± 1 standard deviation.  Asterisks identify statistically 
significant differences between groups (p < 0.015, Student’s t-test). 
 
 
 
 
38 
 
Figure 1:3 Aural cyanosis or "blue ear". 
The photograph in panel A is representative of the ear discoloration associated with aural 
cyanosis during PRRSV infection. The photograph was taken at 11 days after virus challenge. 
For the purpose of comparison, a normal ear is shown (B). 
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Figure 1:4 Clinical outcomes in vaccinated and non-vaccinated groups after dual challenge 
with PRRSV and PCV2. 
Clinical signs were assessed as described in the materials and methods. 
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Figure 1:5 Assessment of lung pathology at 11 days after PRRSV/PCV2 challenge. 
The results are from 10 vaccine (black bars) and 10 non-vaccine (open bars) pigs randomly 
removed from the study at 11 days. The results show the assessment of pneumonia as percent of 
gross lung involvement and histopathology score. Results are shown as mean ± standard 
deviation. The differences between vaccine and non-vaccine groups were not significant (p > 
0.05). 
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Figure 1:6 Gross and microscopic lesions associated with PCVAD. 
The results are representative of PCVAD-affected pigs necropsied between 32-42 days after 
combined PRRSV and PCV2 challenge. (A) Shows a set of lungs from a challenged pig with 
pneumonia, mottling and consolidation.  A normal lung from an age-matched pig is shown for 
comparison.  (B)  H&E-stained lung from a challenged pig showing moderate to severe 
multifocal interstitial pneumonia with lymphohistiocytic infiltration of alveolar septa.  A normal 
lung is shown for the purpose of comparison.  (C) Lymphoid depletion in lymph node from a 
challenged pig.  A normal lymph node with prominent germinal centers (GC) is shown for the 
purpose of comparison.  (D) Immunohistochemical staining showing the accumulation of PCV2 
antigen in lung and lymph node from a challenged pig.  
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Figure 1:7 PCV2 CP(160-233)/CP(43-233) ratio at 42 days after co-infection. 
Sera were analyzed for anti-PCV2 CP antibodies. The serum antibody ratio was calculated as 
MFI for reactivity with the CP(160-233) decoy epitope divided by the MFI for the CP(43-233) 
conformational antigen. The difference between the means for the PRRS vaccinated and non-
vaccinated groups was significant (p = 0.0006, Student’s t-test).   
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Figure 1:8 Weekly average daily gain (ADG) before and after virus challenge. 
The mean ADG values for no vaccine (open bars) and vaccine (black bars) groups were 
calculated on a weekly basis. The results show mean and standard deviation. The numbers below 
the figure are the number of pigs used in the analysis. Asterisks identify statistically significant 
differences in ADG between groups, p < 0.03, Student’s t-test. 
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Chapter 2 - Microbiome associations in pigs with the best and 
worst clinical outcomes following co-infection with porcine 
reproductive and respiratory syndrome virus (PRRSV) and 
porcine circovirus type 2 (PCV2) 
 Abstract  
On a world-wide basis, co-infections involving porcine reproductive and respiratory 
syndrome virus (PRRSV) and porcine circovirus type 2 (PCV2) are common and contribute to a 
range of polymicrobial disease syndromes in swine.  Both viruses compromise host defenses, 
resulting in increased susceptibility to infections by primary and secondary pathogens that can 
affect growth performance as well as increase morbidity and mortality.  An experimental 
population of 95 pigs was co-infected with PRRSV and PCV2.  At 70 days post-infection (dpi), 
20 representative pigs were selected as having the best or worst clinical outcome based on 
average daily gain (ADG) and the presence of clinical disease.  Worst clinical outcome pigs had 
prolonged and greater levels of viremia as measured by qPCR.  Serum, lung and fecal samples 
collected at 70 dpi were analyzed using DNA microarray technology to detect over 8,000 
microbes.  An increased number of pathogens were detected in serum from pigs in the worst 
performing group.  At the level of the fecal microbiome, the overall microbial diversity was 
lower in the worst clinical outcome group.  The results reinforce the importance of pathogen load 
in determining clinical outcome and suggest an important role of microbial diversity as a 
contributing factor in disease.    
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 Introduction 
On a global basis, co-infections involving porcine circovirus type 2 (PCV2) and porcine 
reproductive and respiratory syndrome virus (PRRSV) are common in growing pigs and 
contribute to a range of polymicrobial disease syndromes.  PCV2 is a single-stranded DNA virus 
in the family Circoviridae which contributes to a group of  disease syndromes collectively 
termed porcine circovirus associated disease or PCVAD (Baekbo et al., 2012).  Although PCV2 
is essential for PCVAD, PCV2 infection alone rarely results in clinical signs and co-pathogens 
are often necessary for disease expression (Opriessnig and Halbur, 2012).  Three important 
syndromes associated with PCVAD include PCV2-associated respiratory disease, poor growth 
performance, and postweaning multisystemic wasting syndrome (PMWS) (Baekbo et al., 2012; 
Ramamoorthy and Meng, 2009; Segales, 2012).  The hallmark lesion of PCVAD is lymphoid 
depletion (Opriessnig and Langohr, 2013), which reduces the ability of the host to respond to 
primary and secondary pathogens.  Since 2006, the application of PCV2 vaccines has largely 
controlled PCVAD in North America and Europe.  However, the disease still maintains a global 
impact, especially in countries without vaccination programs.  
PRRSV is a single-stranded RNA virus in the family Arteriveridae (Benfield et al., 1992; 
Conzelmann et al., 1993) and causes the single most costly disease affecting swine production 
worldwide (Chand et al., 2012).  Losses due to PRRSV infection are associated with increased 
mortality and reduced growth rates due to respiratory disease in weaned pigs (Holtkamp et al., 
2013).  PRRSV infection also contributes to a number of immunological outcomes that increase 
the susceptibility of the host to secondary infections by primary and secondary pathogens 
(Gomez-Laguna et al., 2013; Opriessnig et al., 2011; Renukaradhya et al., 2010).  PRRSV is 
frequently isolated along with PCV2 in the field (Pallares et al., 2002) and is one of the major co-
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factors linked with increasing PCV2 replication and pathogenesis (Allan et al., 2000; Harms et 
al., 2001; Niederwerder et al., 2015; Rovira et al., 2002; Trible et al., 2012).  Clinical outcome 
following co-infection with PRRSV and PCV2 is often subclinical, with overt clinical disease 
occurring in only a subpopulation of pigs.  Morbidity varies drastically, from subclinical 
infections and reduced growth performance to increased mortality.  Host genetics, immunity, 
environmental stressors and secondary pathogens are all factors which can impact clinical 
outcome following PRRSV or PCV2 infections (Boddicker et al., 2012; Chand et al., 2012; 
Opriessnig and Halbur, 2012; Patterson et al., 2015; Rowland et al., 2012).   
An emerging area of study is understanding the role of the microbiome in health and 
disease.  Recent studies have demonstrated that microbiome plays a role in the response of swine 
to experimental inoculation with the bacterial pathogens Mycoplasma hyopneumoniae, 
Salmonella enterica and Brachyspira hampsonii (Bearson et al., 2013; Costa et al., 2014; 
Schachtschneider et al., 2013).  Shifts in the abundance of bacterial populations or changes in the 
microbiome diversity were found to have associations with systemic immune response, pathogen 
shedding, and the development and severity of clinical disease.  In the current study, we took 
advantage of a population of experimentally infected pigs to evaluate differences between the 
best and worst clinical outcomes following co-infection with PRRSV and PCV2.   
 
 Materials and Methods 
Animals and housing. Experiments involving animals and viruses were performed in 
accordance with the Federation of Animal Science Societies (FASS) Guide for the Care and Use 
of Agricultural Animals in Research and Teaching, the USDA Animal Welfare Act and Animal 
Welfare Regulations, and approved by the Kansas State University Institutional Animal Care and 
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Use Committees and Institutional Biosafety Committees.  The study was conducted as part of a 
project to evaluate the role of host genetics in determining the outcome following co-infection 
with PRRSV and PCV2.  Four week-old barrows (n = 95; average age 26.8 ± 2.0 days) were 
obtained from a high-health commercial source negative for PRRSV.  While pigs were derived 
from a sow herd previously vaccinated with a PCV2 capsid subunit vaccine, the piglets were not 
vaccinated for PCV2 and were utilized in the study without regards to the presence of maternal 
antibody.  All pigs were housed in one environmentally controlled room at the Kansas State 
University Large Animal Research Center, and maintained under BSL-2 conditions.  The room 
was chemically disinfected, cleaned with a high heat pressure washer and gas decontaminated 
with vaporized hydrogen peroxide prior to use.  The room was empty for approximately 9 weeks 
prior to the start of the study.  Pigs were housed in 10 pens, each 144 sq ft with 9-10 pigs per 
pen.  Pigs were given access to food and water ad libitum.    
Challenge inoculum. The PRRSV and PCV2b isolates used to prepare the inoculum 
were originally derived from the lymph node of a pig with severe PMWS, as described 
previously (Trible et al., 2011; Trible et al., 2012).  PRRSV (isolate KS62, GenBank Accession 
#KM035803) was isolated by propagation on MARC-145 cells.  Since wild-type PCV2b 
(Genbank Accession #JQ692110) does not propagate to high levels in cell culture, we took 
advantage of the heat stability of PCV2 to make a virus preparation from a lymph node 
suspension enriched for PCV2.  The suspension was heat-treated at 55
o
 C for 30 minutes to 
remove PRRSV, bacteria and other heat-labile agents.  The treated homogenate was recombined 
with the isolated PRRSV to infect cesarean-derived, colostrum-deprived (CD/CD) pigs.  A 
combination lung/lymph node homogenate was prepared from the CD/CD pigs and PRRSV and 
PCV2 were isolated from the homogenate by the methods described above.  Analysis of the heat-
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treated preparation for common agents showed that the preparation was negative for most heat 
stable agents, such as parvovirus, but still positive for torque teno sus viruses (TTSuV) and 
porcine endogenous retroviruses (PERVs) on DNA microarray (Jaing et al., 2015).  Both TTSuV 
and PERV are ubiquitous to swine.   
PRRSV was titered on MARC-145 cells.  Briefly, virus was serially diluted 1:10 in MEM 
(Corning) supplemented with 7% FBS (Sigma-Aldrich), Pen Strep (80 Units/ml and 80 μg/ml, 
respectively; Gibco), 3 ug/ml Fungizone (Gibco), and 25 mM HEPES (Life Technologies).  The 
dilutions were then added in quadruplicate to confluent MARC-145 cells in a 96 well tissue 
culture plate (BD Falcon).  Following a 4 day incubation at 37
o
C in 5% CO2, wells were 
examined for PRRSV induced cytopathic effects, and the 50% tissue culture infectious dose 
(TCID50/ml) was calculated using the method of Reed and Muench (Reed and Muench, 1938). 
The quantity of PCV2 was determined by titration on swine testicle (ST) cells.  Briefly, 
serial 10-fold dilutions of the PCV2 challenge stock were plated in quadruplicate to rapidly 
dividing ST cells in a 96 well tissue culture plate (BD Falcon).  Dilutions were prepared in 
EMEM (Sigma-Aldrich) supplemented with 7% FBS (Sigma-Aldrich) and 50 μg/ml of 
gentamycin (Lonza).  Following a three day incubation at 37
o
C in 5% CO2, cells were fixed and 
permeabilized with 80% acetone and then stained with fluorescein isothiocyanate (FITC)-labeled 
porcine anti-PCV (Veterinary Medical Research and Development, Inc.).  Infected cells were 
visualized using an inverted fluorescent microscope and the TCID50/ml was calculated using the 
method of Reed and Muench (Reed and Muench, 1938). 
Animal model and experimental design. A total of 95 pigs were randomly allocated 
into 10 identical pens using a random number assignment protocol and housed in groups of 9-10 
pigs per pen.   After acclimating for two weeks, all pigs were challenged with a combination of 
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PRRSV and PCV2b.  The challenge viruses were recombined to yield a 2 ml dose consisting of 
10
3.6
 TCID50 PCV2 and 10
5
 TCID50 PRRSV in MEM.  The 2 ml dose was split with 1 ml 
administered intranasally and the remaining 1 ml administered intramuscularly.  Individual body 
weights were collected on -14, -7, 0, 7, 14, 21, 28, 35, 42, 49, 56, 63, and 70 days post-infection 
(dpi).  Blood samples were collected from all pigs on 0, 4, 7, 11, 14, 21, 28, 35, 42, 56 and 70 
dpi.  At 63 dpi, 20 pigs were selected from the surviving 78 pigs and categorized as having the 
best or worst clinical outcomes.  The 10 best clinical outcome pigs were selected due to having 
the highest average daily gain (ADG) from 0-63 dpi and due to a complete lack of overt clinical 
disease during the post-challenge period.  The 10 worst clinical outcome pigs were selected due 
to having the lowest ADG from 0-63 dpi and due to having at least 10 days of moderate to severe 
clinical disease during the post-challenge period.  All 20 pigs were humanely euthanized on 70 
dpi and complete necropsies were performed. 
Clinical Disease and Pathology. Pigs were evaluated daily for the presence of clinical 
signs, including dyspnea, aural cyanosis, coughing, nasal discharge, open mouth breathing, poor 
body condition, muscle wasting, pallor or jaundice, lameness, joint effusion, depression and 
lethargy.  Each pig was visually examined by a veterinarian or veterinary assistant each day 
during the study period.  Appropriate treatments were initiated for pigs that presented with 
moderate to severe clinical disease.  Examples of clinical presentations where treatment was 
administered included: 1. Difficult respiration, 2. Mucoid nasal discharge, 3. Lameness with 
associated joint effusion, 4. Pallor or jaundice associated with muscle wasting, and 5. Lethargy 
or depression with a rectal temperature ≥104°F.  For clinically affected pigs, antibiotic therapy 
was administered, including ceftiofur hydrochloride for respiratory or systemic disease and 
oxytetracycline for infectious arthritis.  All pigs with overt clinical disease and rectal 
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temperatures ≥104°F were administered flunixin meglumine, a nonsteroidal anti-inflammatory 
drug (NSAID).  Pigs with intractable fevers of greater than 4 days duration were given a 2 day 
wash-out period and then administered oral meloxicam.  Clinical signs and systemic treatments 
unrelated to PRRSV/PCV2 co-infection (e.g. lacerations, dermatitis, hoof wounds, congenital 
hernias) were documented but were not considered as clinical disease in selecting the best and 
worst outcome groups.  Animals were humanely euthanized with pentobarbital sodium.  
Complete necropsies were performed by a board certified pathologist who was blinded as to the 
source of the pigs.  Pigs that died or were humanely euthanized due to pathology unrelated to 
PCV2/PRRSV co-infection (e.g. gastric torsion, non-infectious lameness, etc.) were excluded 
from the study.  Average daily gain (ADG) was calculated as the change in weight divided by the 
number of days and was reported in kg. 
Measurement of PRRSV and PCV2 viremia. Viral DNA and RNA were extracted 
simultaneously from 50 μL of serum using Ambion’s MagMAX 96 Viral Isolation Kit (Applied 
Biosystems) in accordance to the manufacturer’s instructions.  PRRS viral RNA was quantified 
using EZ-PRRSV MPX 4.0 Real Time RT-PCR Target-Specific Reagents (Tetracore) according 
to the manufacturer’s instructions.  For consistency, each plate contained Tetracore 
Quantification Standards and Control Sets for use with EZ-PRRSV MPX 4.0 RT-PCR Reagents.  
All PCR reactions were carried out on a CFX96 Touch Real-Time PCR Detection System (Bio-
Rad) in a 96-well format using the recommended cycling parameters.  PCV2 DNA was 
quantified using SsoAdvanced Universal SYBR Green Supermix (Bio-Rad).  Forward and 
reverse PCR primers were 5’-AATGCAGAGGCGTGATTGGA-3’ and 5’-
CCAGTATGTGGTTTCCGGGT-3’, respectively.  Primers were used at a final concentration of 
300 μM.  Nuclease free water was used to bring the mastermix volume to 18 μL per reaction.  
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The addition of 2 μL of template nucleic acid brought the final reaction volume for each sample 
to 20 μL.  Standard curves and positive and negative controls were included on each plate.  
Plasmid DNA was used for the PCV2 standard curve and positive control template.  DNA 
inserted into the plasmid was obtained from a field strain of PCV2 (PCV2b 321/393).  Plasmid 
DNA was isolated using the PureYield Plasmid Miniprep System (Promega) according to the 
manufacturer’s instructions.  The DNA for the standard curve was quantified using a NanoDrop 
8000 Spectrophotometer.  The standard curve was produced by diluting the purified plasmid 
DNA 1:1000 in nuclease free water followed by five serial 1:10 dilutions in nuclease free water.  
The final standard curve contained 6 points ranging from 10
7
 to 10
2
 logs of template DNA which 
produced threshold crossing values between 15 and 33 cycles.  Standard curves were run in 
duplicate with nuclease free water as a negative control.  The PCV2 PCR was carried out on a 
CFX96 Touch Real-Time PCR Detection System using the following settings: activation at 98°C 
for 2 minutes, followed by 40 cycles of denaturing at 98°C for 5 seconds and 
annealing/extension at 60°C for 10 seconds.  The melting curve was performed between 65-95°C 
using 0.5°C increments.  The PCR assay results were reported as log10 PRRSV RNA starting 
quantity (copy number) per 50 μL reaction volume or log10 PCV2 DNA starting quantity per 20 
μL reaction volume. 
DNA Microarray analysis. Each 1 mL sample for extraction consisted of 250 µL 
sample and 750 µL of Trizol LS reagent
 
(Life Technologies).  The purpose of adding Trizol was 
to inactivate all viruses and bacteria in tissue, fecal and serum samples so they could be shipped 
to Lawrence Livermore National Laboratory for molecular analysis.  Nucleic acid purification 
could also be performed using commercially available kits, but only the Trizol method was used 
in this study.  Each sample was brought to room temperature, 200 µL of chloroform was added, 
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and the tube was shaken vigorously for 15 seconds.  Samples were incubated at room 
temperature for 15 min and then centrifuged at 12,000xg for 15 min at 4°C.  The upper aqueous 
layer was removed by pipetting and placed in a new tube for RNA extraction.  The lower phases 
were saved for DNA extraction.  For RNA extraction, 10 µg of glycogen was added to the 
aqueous phase along with 500 µL of 100% isopropanol.  Following 10 min incubation, samples 
were centrifuged for 10 minutes at 12,000xg and 4°C.  The supernatant was removed and the 
RNA pellet was washed with 1 mL of 75% ethanol.  The sample was vortexed and centrifuged at 
7500xg for 5 minutes at 4°C.  Following centrifugation, the supernatant was removed and the 
RNA was air dried for 10 min.  RNA pellets were re-suspended in DEPC water and RNA 
concentration was determined by the Qubit fluorometer (Life Technologies).    
For DNA isolation, 300 µL of 100% ethanol was added to the interphase/organic phase, 
the tube was inverted several times, and incubated for 3 min at room temperature.  Samples were 
centrifuged at 2000xg for 5 min at 4°C and the supernatant was discarded.  The DNA pellet was 
washed with 1 mL sodium citrate/ethanol solution (0.1M sodium citrate in 10% ethanol, pH 8.5), 
incubated for 30 min at room temperature, centrifuged at 2000xg for 5 min at 4°C, and the 
supernatant was removed.  The sodium citrate/ethanol wash procedure was repeated once more.  
Following the wash procedures, 2 mL of 75% ethanol was added to the pellet and incubated at 
room temperature for 20 min and centrifuged at 2000xg for 5 min at 4°C.  The supernatant was 
removed and the samples were air dried for 10 min.  DNA pellets were resuspended in 8 mM 
NaOH solution and the DNA concentration was determined by the Qubit fluorometer.  
For each lung sample, 10 µL (approximately 7.0-12.0 µg) of extracted RNA was used as 
input to generate double stranded cDNA following the standard Roche NimbleGen protocols.  
Briefly, first strand cDNA was generated followed by second strand synthesis.  Next, the cDNA 
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was treated with RNase A and precipitated.  After cDNA generation, 500 ng each of cDNA and 
DNA was mixed and labeled as detailed below. 
Since less extracted nucleic acid was obtained from the fecal and serum samples, a 
random amplification was performed on these samples as described previously (Rosenstierne et 
al., 2014).  For each amplification reaction, 5µL each of extracted DNA and RNA was input into 
the reaction.  The amplified DNA was purified using the Qiaquick PCR purification columns 
(Qiagen) and the yield was determined by the Qubit fluorometer. 
Approximately 400-500 ng of amplified cDNA and DNA were mixed together and 
labeled using a one-color labeling kit
 
(One-Color Labeling kit, Roche NimbleGen) following the 
standard manufacturer’s protocols.  Following the labeling reaction, a hybridization reaction was 
prepared with 10µg of each labeled DNA and Roche NimbleGen hybridization reagents 
following the standard manufacturer’s protocols.  The MDAv5 12x135K microarray (Roche 
NimbleGen) was utilized for this work and samples were loaded onto the array and allowed to 
hybridize for 65 hr at 42°C in a Roche NimbleGen Hybridization System set to mix mode B.  
After hybridization, the microarrays were washed following standard manufacturer protocols 
with Roche NimbleGen wash buffers.  Each array was washed for 2 minutes and 15 seconds in 
Wash 1 at 42°C followed by 1 min in Wash 2 at room temperature and 15 seconds in Wash 3 at 
room temperature.  After washing, the microarrays were exposed to a stream of nitrogen gas to 
remove any particulates from the array surface.  Microarrays were scanned on a microarray 
scanner
 
(MS200 microarray scanner, Roche NimbleGen) at a resolution of 2 µM.     
 Microarray data were analyzed using the composite likelihood maximization method 
(CLiMax) developed at Lawrence Livermore National Laboratory (Gardner et al., 2010).  The 
log likelihood for each of the possible targets is estimated from the BLAST similarity scores of 
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the array feature and target sequences, together with the feature sequence complexity and other 
covariates derived from the BLAST results (Gardner et al., 2010).  Presented are the data for 
microbe sequences that were equal to or greater than the 99% threshold.  
Statistical analyses. All statistical analyses were performed using GraphPad Prism 6.00 
software.  Body weights, ADG, viremia and area under the curve were analyzed and compared 
between groups using the unpaired t-test.  Microbial families detected in feces were compared 
between groups using the Mann-Whitney U-test.  Correlation analyses were performed using 
Pearson correlation coefficients and linear regression.  Proportions of individual microbe species 
detected in each group were compared using Fisher’s exact test, and the expected false discovery 
rate (FDR) was calculated using the Benjamini-Hochberg method to correct for multiple testing.   
  
 Results 
Selection of pigs with the best and worst outcome. Clinical disease and weight gain 
were used as the criteria for the selection of the two groups of pigs used in the study.  The time 
course of clinical disease after co-infection of the 95 pigs with PRRSV and PCV2 is summarized 
in Figure 1.  The pattern of clinical signs over time reflected the acute disease associated with 
PRRS followed by the later onset of PCVAD.  Throughout the study period, 33 pigs (33/95; 
35%) exhibited clinical signs severe enough to receive at least one day of systemic veterinary 
treatment.  Supportive therapy was administered in the form of antibiotics and/or NSAIDS to 
reduce secondary bacterial infections, inflammation, and pyrexia.  Seventeen of the 33 treated 
pigs (51.5%) died or were euthanized prior to the end of the 70 day study.  Euthanasia was 
performed as a result of being moribund or nonresponsive to treatment.  Of the 16 remaining 
treated pigs, 10 pigs were selected based on having the lowest ADG.  The clinical signs in the 10 
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worst outcome pigs are summarized in Table 1.  Overall, the clinical outcomes were 
representative of the disease syndromes associated with PRRSV and PCV2 co-infection.  
Clinical disease progression in the 10 worst outcome pigs is shown in Figure 1C and on the 
whole, clinical disease in this group mirrored the clinical disease that appeared in the entire 
population (n = 95, see Figure 1A).  Two clinical disease phases are evident post-infection.  First, 
peaking between 10-20 dpi were clinical signs consistent with acute PRRSV infection, such as 
respiratory distress and aural cyanosis.  Second, peaking between 32-42 dpi were clinical signs 
consistent with PCVAD, such as pallor or jaundice and decreased body condition.  All pigs in the 
worst clinical outcome group showed signs of dyspnea and rhinorrhea.  The majority of the worst 
outcome pigs showed signs of lethargy or depression, decreased body condition, pyrexia, 
coughing, and diarrhea.  All 10 pigs received between 2-4 doses of ceftiofur and 4 pigs received 
between 2-6 doses of oxytetracycline.  The best clinical outcome pigs did not receive antibiotics 
or NSAIDs during the pre and post-infection period and showed no evidence of clinical disease.  
The ADG values for the 10 best and 10 worst clinical outcome pigs over the 70 day post-
infection period are shown in Table 2.  The mean ADG for the 10 worst clinical outcome group 
was 0.475 ± 0.15 kg compared to 0.837 ± 0.04 kg for the 10 best clinical outcome pigs.  The 
difference between the means was highly significant (p < 0.0001, unpaired t-test). 
At the end of the 70 day study period, necropsies were performed on all 20 pigs.  All 10 
of the worst outcome pigs had gross lesions consistent with PRRS, PCVAD, or virus associated 
immunosuppression, such as polyserositis.  Specifically, gross lesions in the worst outcome 
group included moderate to diffuse fibrous adhesions between the lungs and thoracic cavity 
and/or the pericardium (6 pigs), moderate interstitial pneumonia (4 pigs), multifocal fibrous 
adhesions in the abdomen (4 pigs), and granulomatous nephritis (1 pig).  In the best clinical 
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outcome pigs, 8 of the 10 pigs showed no significant gross lesions.  In the remaining two pigs, 
both had multifocal fibrous adhesions in the abdomen, one had a splenic infarction, and one had 
diffuse fibrous adhesions on the pericardium.        
Mean weights for the two groups are show in Figure 2.  By the end of the study, the mean 
weights for the best and worst outcome groups were 72.3 ± 3.8 kg and 43.0 ± 11.3 kg, 
respectively.  The 29 kg difference was highly statistically significant (p < 0.0001, unpaired t-
test).  Even though the best and worst performing pigs were selected at the end of the study, the 
means of the two groups were significantly different at all other time points, including prior to 
infection.  For example, the means for the best and worst outcome pigs at two weeks before 
infection were 6.9 ± 1.0 kg and 5.5 ± 1.1 kg, respectively (p = 0.008, unpaired t-test).  As shown 
by the standard deviation bars, the mean weights in the best clinical outcome group were more 
uniform throughout the study period compared to the worst clinical outcome group.  A 
regression line was fit to the mean weights for both groups over time.  The greatest deviation 
from the estimated line appeared at between weeks 5 and 6 for the worst outcome group, which 
correlated with peak PCVAD (see Figure 1C). 
PRRSV and PCV2 viremia. The results for PRRSV and PCV2 viremia are shown in 
Figure 3.  PRRSV infection in the best outcome pigs followed the typical course, peaking at 
between 7 and 11 dpi then followed by a decay to less than 1 log10 copies/PCR reaction after 21 
dpi (see Figure 3).  The worst clinical outcome pigs had a slight delay in viremia, peaking at 
around 14 dpi, but with prolonged and increased viremia throughout the remainder of the study.  
A significant difference between the two groups was shown on 28 dpi, when mean PRRSV 
viremia was 2.46 and 0.86 log10 copies/PCR reaction for the worst and best outcome groups, 
respectively (p = 0.015, unpaired t-test).  After the initial decay, rebound peaks were observed in 
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several pigs, a phenomenon initially described in 2010 (Reiner et al., 2010) and later by us 
(Boddicker et al., 2012).  Another way to present infection is through the calculation of virus 
load or the area under the viremia curve (Boddicker et al., 2012).  The total viral load for each of 
the 20 pigs was quantified as the area under the curve (AUC) from 0 to 70 dpi (data not shown).  
The range for the best and worst outcome groups was 88.0 – 151.7 and 95.5 – 245.9, 
respectively.  The means for the best and worst outcome groups were significantly different 
(116.2 and 153.5, respectively; p = 0.04, unpaired t-test), further demonstrating that PRRS virus 
replication was higher in the worst outcome group. 
The results for PCV2 viremia are presented in Figure 3B.  Unlike PRRSV, PCV2 viremia 
shows a delay in peak replication, but is maintained at fairly high levels in the blood for an 
extended period of time (>3 log10 copies/PCR reaction between 14-70 dpi for the worst clinical 
outcome group).  Both groups showed a peak in PCV2 viremia between about 21 and 42 dpi.  
Even though not significantly different, the worst clinical outcome group maintained a higher 
peak virus level.  A significant increase in PCV2 viremia for the worst outcome group was only 
observed on 14 dpi when mean virus levels were 3.44 and 1.74 log10 copies/PCR reaction for the 
worst and best outcome groups, respectively (p = 0.03, unpaired t-test).  Comparing the virus 
loads or AUC for the two groups showed a significant increase in total PCV2 replication in the 
worst outcome group; means were 210.9 and 260.7 for the best and worst outcome groups, 
respectively (p = 0.02, unpaired t-test).  The range AUC values for the best and worst outcome 
groups were 154.8 – 305.5 and 187.9 – 350.1, respectively.  Together, these data show that the 
amount of virus is increased in the worst outcome pigs.                
DNA microarray results for serum. DNA microarray results for microbial species 
detected in serum, feces and lung are presented in Figures 4 through 7.  The results for each 
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bacterium or virus were ranked according the highest log likelihood score and the first species in 
each microbe family with the greatest percentage of target-specific probes is shown.  The results 
for serum at day 70 are shown in Figure 4.  The results for bacteria identified Bacillus cereus as 
being detected at a significantly higher rate in the worst outcome pigs (7 of 10 pigs) compared to 
only one positive pig for the best outcome group (p = 0.02, Fisher’s exact test; B-H FDR = 0.36).  
Some strains of Bacillus cereus are considered nonpathogenic but others have been implicated in 
cases of human foodborne illness (Berthold-Pluta et al., 2015).  For viruses, all pigs showed the 
presence of torque teno sus virus (TTSuV) and porcine endogenous retrovirus (PERV), which 
are ubiquitous and were also present in the virus inoculum used for challenge. 
In general, the PCR results for PRRSV and PCV2 were similar to the microarray.  For 
example, at 70 dpi, mean PCV2 viremia was 2.3 and 3.3 log10 copies/PCR reaction for the best 
clinical outcome and worst clinical outcome groups, respectively.  The microarray detected 
PCV2 in the serum of 8 best outcome pigs and all 10 worst outcome pigs.  The two best clinical 
outcome pigs negative for PCV2 on the microarray had 0 and 1.8 log10 copies/PCR reaction, 
which are levels under the threshold of detection by microarray (Jaing et al., 2015).   
With regards to PRRSV, by 70 dpi, the majority of pigs showed undetectable levels of 
PRRSV in the blood.  PRRSV was detected by microarray in only one best outcome pig and one 
worst outcome pig.  The corresponding PCR values for those two pigs were 2.4 and 2.0 log10 
copies/PCR reaction, respectively, which is near the threshold for detection of PRRSV by 
microarray (Jaing et al., 2015).  The values for all other pigs were lower. 
DNA microarray results for lung. Viral and bacterial species detected by microarray in 
lung samples are shown in Figure 5.  Only 6 species were detected with no significant 
differences between the two groups.  The microarray detected PCV2 in all worst outcome pigs 
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and in 8 of the best outcome pigs.  By 70 dpi, PRRSV was undetectable in the lungs of all pigs.  
Porcine endogenous retrovirus A was detected in all pigs and torque teno sus virus was detected 
in 5 best outcome and 2 worst outcome pigs.  Bacterial species were rare; 3 of the worst outcome 
pigs and 1 of the best outcome pigs had bacteria detected in lung samples.      
DNA microarray results for feces. A total of 28 bacterial species were detected by the 
array.  Those bacteria that were only found at a low prevalence (10% or less) included 
Mannheimia haemolytica, Dechlorosoma suillum, Campylobacter lari, Erwinia amylovora, 
Brevibacillus brevis, Enterococcus faecalis, Dorea formicigenerans, Solibacillus silvestris and 
Bacteroides fragilis.  The remaining bacteria are listed in Figure 6.  Several bacteria, such as 
Prevotella copri, Treponema succinifaciens, Phascolarctobacterium sp., Megasphaera elsdenii, 
Faecalibacterium prausnitzii, and Lactobacillus johnsonii, were present at a relatively high 
prevalence; i.e. > 50% of pigs.  The most interesting finding was the presence of Escherichia coli 
in 5 best outcome pigs but not detected in any member of the worst outcome group (p = 0.03, 
Fisher’s exact test; B-H FDR = 0.98).  Although some strains of E. coli are enteropathogenic and 
cause diarrhea in piglets, there were no toxin genes detected.  In serum, Bacillus cereus was 
detected at a relatively high prevalence in the worst outcome pigs (see Figure 4); however, in the 
feces, the higher prevalence was in the best performing group. 
Viral species detected in the feces of both groups are also shown in Figure 6.  Although 
these pigs were from a herd with a recent PED outbreak, PEDV was not detected by microarray 
in any of the pigs in the two groups.  PCV2 was detected in the feces, with a higher prevalence in 
the worst outcome group.  PRRSV was not detected.  Several of the ubiquitous viruses were 
detected, including torque teno sus virus 1b and porcine type C retrovirus.  A variety of other 
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viruses were detected at different frequencies, including porcine kobuvirus, porcine bocavirus, 
porcine astrovirus, po-circo-like virus, porcine teschovirus and porcine enterovirus.       
Microbiome diversity was calculated by quantifying the number of microbial families 
detected in each fecal sample.  The results are presented in Figure 7.  The range of microbial 
families detected for the best outcome and worst outcome groups were 10 – 16 and 7 – 12, 
respectively.  The best clinical outcome group had significantly greater family diversity than the 
worst clinical outcome group (p = 0.017, Mann-Whitney U-test). 
  
 Discussion 
Co-infections involving PCV2 and PRRSV contribute to PCVAD, associated with 
significant losses through increased mortality and poor growth performance.  In acute outbreaks 
of PCVAD in the field, the prevalence of clinically ill pigs is typically only 2-25% (Kyriakis et 
al., 2002; Quintana et al., 2001; Sorden et al., 1998).  In a previous study by us, co-infection with 
PRRSV and PCV2 resulted in 12-26% of pigs showing clinical signs of PCVAD (Niederwerder 
et al., 2015).  Thus, the majority of pigs are able to support virus replication without overt 
clinical disease.  Understanding the factors that influence how a pig responds to virus challenge, 
through subclinical or clinical infections, was a primary goal of this study.  Specifically, we 
sought to compare microbiome and pathogen load between those pigs which were classified as 
having the best or worst clinical outcome following co-infection with PRRSV and PCV2 in a 
controlled experimental trial.     
The best and worst clinical outcome groups were selected based on ADG and clinical 
disease after virus challenge.  As such, it is interesting to note that there were significant 
differences between the mean weights of the two groups in the weeks prior to challenge.  
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Presumably, factors unrelated to co-infection were affecting weight gain in the worst outcome 
group during these two weeks.  These factors may include host genetics, pathogen exposure and 
environmental conditions prior to arrival, or immunity.  However, differences between the 
growth rates of the two groups become most prominent during peak PCVAD.  Between 28-35 
dpi, mean weight gain for the worst performing group was 0.36 kg compared to 6.91 kg for the 
best performing group.  This highlights how the development of clinical disease significantly 
impacts growth.  Further, it is clear that some pigs can thrive while maintaining subclinical 
infections, even during peak virus replication and clinical disease.   
When comparing PRRSV and PCV2 viremia between the two groups, it should be 
considered that primary differences were detected outside of either peak in virus replication.  For 
example, a significant difference was found in PRRSV viremia at 28 dpi, when virus load 
typically decays.  A significant difference was noted for PCV2 at 14 dpi, a time point prior to 
peak virus replication.  This demonstrates that replication patterns may have a more rapid incline 
(PCV2) or a more gradual decline (PRRSV) in poor performing pigs.  However, comparing the 
total virus loads allowed us to demonstrate that overall, virus replication was higher in the worst 
outcome group throughout the entire course of the study.  This data emphasizes the underlying 
importance of viral pathogen load in the determination of outcome after challenge.              
The Lawrence Livermore Microbial Detection Array (LLMDA) technology utilized in 
this study provides the opportunity to test for the presence of over 8000 microbes including 
viruses, bacteria, fungi, protozoa and archaea species.  In our previous work, we confirmed the 
applicability of the microarray in detecting known and unknown pathogens in various diagnostic 
samples from pigs (Jaing et al., 2015).  In the current report, we applied the microarray to serum, 
lung, and fecal samples to investigate differences between groups of pigs with either the best or 
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worst clinical outcome after co-infection.  Overall, the DNA microarray detected the microbial 
signatures of 18 species in serum, 6 species in lung and 39 species in feces.    
In serum, DNA microarray detected Bacillus cereus in a significantly greater proportion 
of worst outcome pigs compared to best outcome pigs.  Because B. cereus is typically present in 
the gastrointestinal tract (phylum Firmicutes), this finding likely represents a generalized 
increase in gastrointestinal permeability of poor performing pigs, allowing bacterial microbes to 
invade the bloodstream.  Our previous microarray work also reported evidence of bacteremia, 
where approximately one third of pigs tested (6/18; 33%) had bacterial signatures detected in the 
serum (Jaing et al., 2015).    
Although pulmonary tissues were long thought of as sterile, the lung microbiome is now 
a well-recognized factor impacting human health and disease of the respiratory tract (Cui et al., 
2014; Dickson et al., 2013).  In infectious diseases such as HIV and non-infectious diseases such 
as chronic obstructive pulmonary disease, lung microbiome profiles have been associated with 
treatment success or clinical outcome (Cui et al., 2014).  The lung is a primary site for both  
PRRSV and PCV2 replication, and modulation of the host immune response to primary and 
secondary pathogens in the lung is known to increase viral pathogenesis (Gomez-Laguna et al., 
2013; Opriessnig and Halbur, 2012).  However, studies to investigate how the lung microbiome 
impacts these viral infections in swine are lacking.  In the current study, very few microbes, 
including only two bacterial species, were detected by DNA microarray in lung.  No significant 
difference was detected that could help explain clinical outcome.  Similarly, Schachtschneider et 
al. (2013) found that the microbiome present in lower respiratory tract samples did not affect 
outcome after challenge with Mycoplasma hyopneumoniae, another common respiratory 
pathogen in swine (Schachtschneider et al., 2013).  The lack of pathogenic and non-pathogenic 
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microbes detected in the lungs from our study may be due to several factors.  First, the DNA 
microarray is less sensitive than PCR and may not detect microbes that are present in low 
numbers.  Therefore, the microarray may not be the best tool for interrogating the porcine lung 
microbiome, where non-pathogenic microbes are likely present in limited quantities.  Second, the 
timing of collection may have impacted microbe detection.  At 70 days post-infection, all 20 pigs 
had cleared PRRSV and although many pigs still had PCV2 detected, all pigs had resolved overt 
clinical disease (compare Figure 1 and Table 5).  Therefore, finding clinically relevant secondary 
bacterial populations in the lung would have been less likely at this time point. 
Although much is still unknown, significant advances have been made in understanding 
the impact of the gastrointestinal microbiome on systemic and respiratory diseases in humans 
(Fujimura and Lynch, 2015; Redinbo, 2014).  Investigating the effects of the microbiome on 
food animal diseases is relatively new and previous studies have primarily focused on bacterial 
pathogens.  For example, a recent study examined the fecal microbiome differences between 
those pigs which did and did not develop mucohemorrhagic diarrhea after inoculation with 
Brachyspira hampsonii.  Pigs which developed mucohemorrhagic diarrhea were associated with 
lower bacterial counts in the feces and a decreased Bacteroidetes:Firmicutes ratio (Costa et al., 
2014).  Schachtschneider et al. (2013) evaluated the effects of orally administering the 
gastrointestinal microbiota from a healthy adult boar to nursery pigs prior to challenge with 
Mycoplasma hyopneumonia.  Oral microbial inoculation increased fecal microbiome diversity, 
resulted in earlier seroconversion, decreased gross lung lesions and significantly reduced 
coughing levels after challenge.  However, there was no significant difference in weight gain 
between the two groups (Schachtschneider et al., 2013).  Bearson et al. (2013) investigated the 
differences in fecal microbiome between those pigs which were classified as high or low 
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Salmonella-shedders after experimental challenge with Salmonella enterica serovar 
Typhimurium.  Low Salmonella-shedders had significantly lower levels of diarrhea, increased 
presence of Ruminococcaceae bacteria in the feces prior to inoculation, and increased Prevotella 
species 2 days after inoculation (Bearson et al., 2013).  Although similarities are present between 
these studies and our study, direct comparisons are difficult as the above studies used 
quantitative PCR in which abundance, and not just detection, can be evaluated.                 
An overall trend described above and continued in our study is the association between 
increased fecal microbe diversity and density with improved outcome.  In the current study, the 
total number of microbial families detected in feces was significantly higher in the best clinical 
outcome group.  Reduced family diversity in the worst clinical outcome pigs may have been due 
to antibiotic treatment for clinical signs during the study period.  Therefore, linear regression 
analysis was performed on the number of antibiotic doses received (independent variable) and 
the number of microbial families detected in feces (dependent variable) for each of the worst 
outcome pigs; no significant associations were detected (data not shown).  Although there does 
not appear to be a significant correlation between antibiotics received and fecal microbial 
diversity, the overall effect of antibiotic administration cannot be eliminated.  However, it would 
be expected that parenteral antibiotic therapy would affect serum and lung samples in a similar 
manner to feces, and reductions were not uniformly observed across all samples collected from 
worst outcome pigs. 
Consistent with previous reports (Holman et al., 2014; Kim et al., 2011), the majority of 
bacterial species detected in feces by the microarray fall within the Firmicutes phylum (18/28 
species).  Although the ratio of Bacteroidetes:Firmicutes has been linked with both weight gain 
and clinical outcome (Costa et al., 2014; Guo et al., 2008), no significant ratio difference was 
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detected between the two clinical outcome groups in this study.  However, these ratios are 
typically calculated by quantifying relative abundance, an analysis we are unable to perform 
using the DNA microarray.  All pigs except one had Lactobacillus sp. and Faecalibacterium 
prausnitzii detected in the feces.  F. prausnitzii is a common anaerobic bacterium, considered 
anti-inflammatory (Sokol et al., 2008) and makes up approximately 5% of all bacteria found in 
human feces (Arumugam et al., 2011).  In contrast, Bacteroides sp. was only detected in one pig, 
whereas it is the most prevalent bacterial genus detected in human feces (Arumugam et al., 
2011).  This is consistent with a previous report showing Bacteroides sp. are detected at a higher 
rate in humans than in swine (Lamendella et al., 2011).  Prevotella sp., the most abundant 
bacterial genus reported in swine feces (Lamendella et al., 2011), was detected at a higher rate in 
best clinical outcome pigs (10/10; 100%) compared to worst clinical outcome pigs (7/9; 78%); 
however, this difference was not statistically significant (p = 0.21; Fisher’s exact test).     
Overall, members of the Proteobacteria phylum, including Escherichia coli, Erwinia 
amylovora, Campylobacter lari, Dechlorosoma suillum, and Mannheimia haemolytica, were 
only detected in the best clinical outcome group feces.  Specifically, E. coli was detected at a 
significantly higher rate in best outcome pigs.  It should be considered that members of this 
phylum potentially contribute to improved clinical outcome and weight gain after co-infection.  
Other studies have found similar associations.  For example, a significant increase in the 
proportion of Proteobacteria was detected in the pre-inoculation feces of pigs which remained 
nonclinical after B. hampsonii challenge (Costa et al., 2014).  In another study, pigs administered 
a medicated diet known to improve feed efficiency had significant increases in bacterial species, 
primarily E. coli, of the Proteobacteria phylum compared to non-medicated pigs (Looft et al., 
2012).  E. coli has also been associated with excessive weight gain in pregnant women 
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(Santacruz et al., 2010) as well as increased body weight and fat deposition in rats (Karlsson et 
al., 2011).  Although this may be an undesirable outcome in studies of obesity, increased weight 
gain associated with E. coli colonization could be extremely valuable within a production 
system.  Whether members of this bacterial phylum truly play a protective role in host response 
and increasing growth performance remains to be investigated.      
The relationship between PCV2 and PRRSV is complex and co-infection with both 
viruses has been shown to increase pathogenicity compared to either virus infection alone 
(Harms et al., 2001).  In the current study, the presence of high serum titers of both PRRSV and 
PCV2 were associated with poor clinical outcome.  Although both viruses contribute to 
modulation of the host immune response and increase susceptibility to primary and secondary 
pathogens, this study highlights how host response to primary virus challenge is a major 
determinant of clinical outcome.  In addition, this study provides valuable insight into how 
microbiome may contribute to outcome following systemic viral infection.    
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Table 2:1 Summary of clinical signs in 10 pigs with worst clinical outcome 
 
  
 
Pigs Affected Duration Range (days) Mean Duration ± SD (days) 
Treatment for Clinical Signs 
Dyspnea 
Rhinorrhea 
Lethargy 
Decreased Body Condition 
Pyrexia 
Coughing 
Diarrhea 
Pallor or Jaundice 
100% 
100% 
100% 
90% 
80% 
80% 
80% 
60% 
50% 
10-29 
3-17 
1-15 
0-22 
0-37 
0-23 
0-11 
0-14 
0-5 
17.5 ± 7.3 
8.9 ± 3.7 
5.4 ± 5.1 
6.3 ± 7.8 
10.8 ± 14.0 
8.3 ± 8.0 
2.5 ± 3.3 
2.4 ± 4.3 
1.3 ± 1.8 
Muscle Wasting 
Open Mouth Breathing 
Lameness 
Joint Effusion 
Aural Cyanosis 
30% 
30% 
20% 
20% 
10% 
0-4 
0-1 
0-22 
0-7 
0-2 
0.9 ± 1.5 
0.3 ± 0.5 
2.3 ± 6.9 
1.1 ± 2.4 
0.2 ± 0.6 
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Table 2:2 Average daily gain between 0-70 dpi 
 
Worst Performing  Best Performing 
Pig ADG  Pig ADG 
1 0.537  6 0.883 
3 0.492  15 0.831 
12 0.149  29 0.827 
16 0.506  30 0.779 
24 0.555  43 0.805 
28 0.542  54 0.903 
47 0.493  55 0.797 
50 0.280  62 0.848 
61 0.495  63 0.889 
88 0.698  98 0.808 
*Mean 0.475  Mean 0.837 
SD 0.153  SD 0.042 
* Significant difference between means, p < 
0.0001, unpaired t-test 
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Figure 2:1 Clinical disease following co-infection with PRRSV and PCV2. 
(A) Percent of pigs receiving treatment as a result of clinical signs (n = 95). (B) Percent survival 
over time (n = 95).  (C) Percent of worst outcome pigs receiving treatment as a result of clinical 
signs (n = 10). 
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Figure 2:2 Mean weights over time for pigs with the best and worst clinical outcomes. 
Data is shown as mean weight ± one standard deviation with regression lines.  Mean weights 
were significantly different between the two groups on every week shown (p < 0.05, unpaired t-
test). 
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Figure 2:3 PRRSV and PCV2 viremia in pigs with best and worst clinical outcomes. 
The figure shows mean PCR values ± 1 standard deviation after challenge with PRRSV and 
PCV2.  Asterisks identify statistically significant differences between groups (p < 0.05, unpaired 
t-test). 
  
80 
 
Figure 2:4 Microarray detection of microbes in serum 70 days after co-infection with PCV2 
and PRRSV. 
Percent of best clinical outcome pigs (n = 10, open bars) and worst clinical outcome pigs (n = 10, 
black bars) are shown for each microbe detected on the array.  Asterisks identify statistically 
significant differences between groups (p = 0.02, Fisher’s exact test). 
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Figure 2:5 Microarray detection of microbes in lungs 70 days after co-infection with PCV2 
and PRRSV. 
Percent of best clinical outcome pigs (n = 10, open bars) and worst clinical outcome pigs (n = 10, 
black bars) are shown for each microbe detected on the array.  No significant differences were 
detected between groups. ND = not detected. 
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Figure 2:6 Microarray detection of microbes in feces 70 days after co-infection with PCV2 
and PRRSV. 
Percent of best clinical outcome pigs (n = 10, open bars) and worst clinical outcome pigs (n = 9, 
black bars) are shown for each microbe detected on the array.  Asterisks identify statistically 
significant differences between groups (p = 0.03, Fisher’s exact test). ND = not detected. 
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Figure 2:7 Fecal microbiome diversity in pigs with the best and worst clinical outcomes. 
Data is shown as the total number of microbial families detected by DNA microarray 70 days 
after co-infection with PRRSV and PCV2.  Group means and standard deviations are represented 
by horizontal lines.  The number of microbial families detected in feces were significantly 
different between the best and worst outcome groups (*p = 0.017, Mann-Whitney U-test). 
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Chapter 3 - Time course of clinical disease and effects on 
growth performance in nursery pigs following co-infection 
with porcine reproductive and respiratory syndrome virus 
(PRRSV) and porcine circovirus type 2 (PCV2) 
 Abstract 
Co-infections involving porcine reproductive and respiratory syndrome virus (PRRSV) 
and porcine circovirus type 2 (PCV2) are common and contribute to several disease syndromes 
that result in a broad range of clinical signs.  The purpose of this study was to standardize 
collection of clinical data in co-infected nursery pigs and investigate the impact of clinical 
disease on animal welfare and growth.  Clinical phenotypes were documented for 476 nursery 
pigs (average age 53.3 ± 6.9 days) after co-infection with PRRSV and PCV2 for 42 days post-
infection (dpi) or until death.  Clinical phenotypes included pallor or jaundice, lethargy or 
depression, muscle wasting, decreased body condition, dyspnea, open mouth breathing, 
rhinorrhea, diarrhea, aural cyanosis, lameness, joint effusion, coughing, and veterinary treatment.  
Other than aural cyanosis, most clinical phenotypes peaked in the second half of the post-
challenge period (21-42 dpi) and corresponded to increased PCV2 replication.  The presence of 
muscle wasting was associated with the greatest reduction (62%) in average daily gain (ADG) 
whereas the duration of dyspnea had the strongest negative association (r = -0.51) with ADG.  
Large reductions in ADG were associated with each day of open mouth breathing (0.227 kg).  
Lameness and aural cyanosis were the only two clinical phenotypes where no significant 
association was detected with ADG for either clinical presence or duration.  In this experimental 
model, respiratory distress and muscle wasting were the clinical phenotypes associated with the 
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greatest impact on growth.  This study provides insight into how detailed clinical observations 
can be used to improve animal welfare and productivity.     
 
 Introduction 
Porcine circovirus type 2 (PCV2), a single-stranded DNA virus in the family 
Circoviridae, contributes to a group of disease syndromes collectively termed porcine circovirus 
associated disease  or PCVAD (Baekbo et al., 2012).  Syndromes associated with PCVAD 
include subclinical reductions in growth or clinical respiratory, enteric, and systemic infections 
(Segales, 2012).  Clinical signs of PCVAD are diverse and may include paleness of the skin, 
icterus, pyrexia, wasting or weight loss, reduced growth rate, ill thrift, diarrhea, cutaneous 
macules and papules, sudden death, dyspnea and other signs of respiratory illness such as 
coughing, sneezing and nasal discharge (Baekbo et al., 2012; Harding, 1997; Opriessnig and 
Langohr, 2013; Ramamoorthy and Meng, 2009; Segales, 2012).  Since inactivated and subunit 
vaccines have been applied to the management of PCV2, PCVAD has been largely controlled in 
North America and Europe (Horlen et al., 2008; Kixmoller et al., 2008; Velasova et al., 2013).  
However, due to the recent emergence of PCV2 strains that escape vaccine protection 
(Opriessnig et al., 2013; Seo et al., 2014) and the lack of consistent vaccination programs in 
some countries, PCVAD remains a global threat to swine production.   
Porcine reproductive and respiratory syndrome virus (PRRSV) is a single-stranded RNA 
virus in the family Arteriveridae (Benfield et al., 1992; Conzelmann et al., 1993).  Syndromes 
associated with PRRSV include subclinical reductions in growth or clinical respiratory and 
systemic infections by primary and secondary pathogens due to PRRSV induced 
immunosuppression (Gomez-Laguna et al., 2013; Opriessnig et al., 2011; Renukaradhya et al., 
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2010).  Clinical signs of PRRS may include cyanosis of the ears and skin, lameness, joint 
effusion, sudden death, pyrexia, inappetence, poor growth performance and signs of respiratory 
illness such as dyspnea, coughing, sneezing, conjunctivitis and nasal discharge (Done and Paton, 
1995; Done et al., 1996; Paton et al., 1991).  Modified live virus vaccines reduce losses 
associated with PRRSV infections.  However, due to several disadvantages to the current 
vaccines, such as incomplete protection against emerging heterologous strains (Wang et al., 
2015) and potentiation of other pathogens (Niederwerder et al., 2015), PRRS continues to be the 
most costly disease to the swine industry (Chand et al., 2012).    
Evaluations of health in a large swine production system are typically nonspecific, such 
as detailing percent mortalities and days in the nursery as key performance indicators (Stalder, 
2013).  Field research studies investigating the clinical signs of PRRSV have reported the 
presence or absence of generalized respiratory disease and mortalities (Rosendal et al., 2014; 
Young et al., 2010).  Detailed information regarding what percent of pigs develop distinct 
clinical signs, such as jaundice or open mouth breathing per month of production, and how these 
numbers are altered during disease outbreaks are widely unknown.  However, detailed clinical 
data collection provides an opportunity for recognizing subtle changes in herd health for early 
intervention and improved outcomes.  Further, defining which clinical signs have the greatest 
impact on growth and welfare may provide guidelines for targeted veterinary treatment and the 
judicious use of antibiotics. 
In this study, we utilized a polymicrobial disease model through co-infection of nursery 
pigs with PRRSV and PCV2 to: 1) Standardize collection of detailed clinical data in a population 
over the time course of infection and 2) Investigate the relationships between specific clinical 
phenotypes with growth performance and animal welfare.    
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 Materials and Methods 
Animals and housing.  Experiments involving animals and viruses were performed in 
accordance with the Federation of Animal Science Societies (FASS) Guide for the Care and Use 
of Agricultural Animals in Research and Teaching, the USDA Animal Welfare Act and Animal 
Welfare Regulations, and approved by the Kansas State University Institutional Animal Care and 
Use Committees and Institutional Biosafety Committees.  Data for the current study was 
compiled from 3 separate trials performed over an 18 month period under similar conditions.  All 
studies were conducted as part of a project to evaluate the role of host genetics in determining 
the outcome following co-infection with PRRSV and PCV2.  Weaned barrows (total n = 476; 
average age of 26.9 ± 3.8 days) were obtained from high-health commercial sources negative for 
PRRSV.  While pigs were derived from sow herds previously vaccinated with a PCV2 capsid 
subunit vaccine, the piglets were not vaccinated for PCV2 and were utilized in the study without 
regards to the presence of maternal antibody.  All pigs were housed in two environmentally 
controlled rooms at the Kansas State University Large Animal Research Center, and maintained 
under BSL-2 conditions.  Pigs were housed in 144 sq ft pens and were given access to food and 
water ad libitum.         
Challenge inoculum. The PRRSV and PCV2b isolates used to prepare the inoculum 
were originally derived from the lymph node of a pig with severe PMWS, as described 
previously (Trible et al., 2011; Trible et al., 2012).  PRRSV (isolate KS62, GenBank Accession 
#KM035803) was isolated by propagation on MARC-145 cells.  The PRRSV component of the 
challenge inoculum, KS62, shared 88.06% identity with the MLV (GenBank Accession 
#AF159149) at the peptide sequence level of GP5.  Since wild-type PCV2b (Genbank Accession 
#JQ692110) does not propagate to high levels in cell culture, we took advantage of the heat 
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stability of PCV2 to make a virus preparation from a lymph node suspension enriched for PCV2.  
The suspension was heat-treated at 55
o
 C for 30 minutes to remove PRRSV, bacteria and other 
heat-labile agents.  The treated homogenate was recombined with the isolated PRRSV to infect 
cesarean-derived, colostrum-deprived (CD/CD) pigs.  A combination lung/lymph node 
homogenate was prepared from the CD/CD pigs and PRRSV and PCV2 were isolated from the 
homogenate by the methods described above.  Analysis of the heat-treated preparation for 
common agents showed that the preparation was negative for most heat stable agents, such as 
parvovirus, but still positive for torque teno sus virus (TTSuV) and porcine oncovirus (PCOV) 
(Jaing et al., 2015), which are ubiquitous.   
PRRSV was titered on MARC-145 cells.  Briefly, virus was serially diluted 1:10 in MEM 
(Corning) supplemented with 7% FBS (Sigma-Aldrich), Pen Strep (80 Units/ml and 80 μg/ml, 
respectively; Gibco), 3 ug/ml Fungizone (Gibco), and 25 mM HEPES (Life Technologies).  The 
dilutions were then added in quadruplicate to confluent MARC-145 cells in a 96 well tissue 
culture plate (BD Falcon).  Following a 4 day incubation at 37
o
C in 5% CO2, wells were 
examined for PRRSV induced cytopathic effects, and the 50% tissue culture infectious dose 
(TCID50/ml) was calculated using the method of Reed and Muench (Reed and Muench, 1938). 
The quantity of PCV2 was determined by titration on swine testicle (ST) cells.  Briefly, 
serial 10-fold dilutions of the PCV2 challenge stock were plated in quadruplicate to rapidly 
dividing ST cells in a 96 well tissue culture plate (BD Falcon).  Dilutions were prepared in 
EMEM (Sigma-Aldrich) supplemented with 7% FBS (Sigma-Aldrich) and 50 μg/ml of 
gentamycin (Lonza).  Following a three day incubation at 37
o
C in 5% CO2, cells were fixed and 
permeabilized with 80% acetone and then stained with fluorescein isothiocyanate (FITC)-labeled 
porcine anti-PCV (Veterinary Medical Research and Development, Inc.).  Infected cells were 
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visualized using an inverted fluorescent microscope and the TCID50/ml was calculated using the 
method of Reed and Muench (Reed and Muench, 1938). 
Experimental Design. Data from a total of 476 nursery pigs were compiled for this 
report from 3 studies (study 1, n = 96; study 2, n = 189; study 3, n = 191).  Pigs in each study 
were randomly allocated into one of two identical rooms using a random number assignment 
protocol and housed in groups of 8-10 pigs per pen.  At approximately 7.5 weeks of age (average 
53.3 ± 6.9 days), all pigs were challenged with a combination of PRRSV and PCV2b.  The 
challenge viruses were recombined to yield a 2 ml dose consisting of 10
3.6
 TCID50 PCV2 and 10
5
 
TCID50 PRRSV in MEM.  The 2 ml dose was split with 1 ml administered intranasally and the 
remaining 1 ml administered intramuscularly.  Twenty-eight days prior to challenge, 39.7% of 
pigs (189/476) were vaccinated with a 2 ml dose of commercial PRRS MLV vaccine (Ingelvac 
PRRS MLV, Boehringer Ingelheim Animal Health; GenBank Accession #AF159149) 
administered intramuscularly according to the vaccine label instructions.  For the purpose of this 
report, medical records and clinical data have been combined for vaccinated and non-vaccinated 
pigs.  All pigs were followed for a total of 42 days post-infection (dpi).  Individual body weights 
were collected weekly on 0, 7, 14, 21, 28, 35, and 42 dpi.  Blood samples were collected on 0, 4, 
7, 11, 14, 21, 28, 35, and 42 dpi and clinical data was collected on a daily basis. 
Clinical Evaluation. Pigs were evaluated daily for the presence of clinical signs 
associated with PRRSV and PCV2 infections.  Every pig was visually examined by a 
veterinarian or veterinary assistant each day of the study period by walking through each pen to 
ensure animals were responsive and ambulatory.  Any pig showing clinical signs of disease was 
restrained for a detailed examination.  A standardized health evaluation questionnaire (see Table 
1) guided evaluators through a series of questions for any pig showing clinical signs of disease.  
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Each clinical phenotype was documented as either yes for presence, no for absence or scored 
based on severity.  Documented clinical phenotypes included dyspnea, aural cyanosis, coughing, 
rhinorrhea, open mouth breathing, pyrexia, decreased body condition, diarrhea, muscle wasting, 
pallor or jaundice, lameness, joint effusion, and depression or lethargy. 
Dyspnea scores were determined based on a 6 point scale as previously described (Halbur 
et al., 1995).  Briefly, 0 = no dyspnea; 1 = mild dyspnea upon restraint; 2 = mild dyspnea at rest; 
3 = moderate dyspnea upon restraint; 4 = moderate dyspnea at rest; 5 = severe dyspnea upon 
restraint; 6 = severe dyspnea at rest.  Lethargy and depression were assessed through response to 
stimuli and interaction with pen mates using a 4 point scale: 0 = bright, alert and responsive; 1 = 
quiet, alert and responsive; 2 = slightly depressed; 3 = depressed; 4 = moribund.  Body condition 
scores (BCS) were assigned using an adapted 5 point scale (Patience and Thacker, 1989).  
Briefly, 1 = emaciated; 2 = thin; 3 = ideal; 4 = fat; 5 = obese.  Lameness was assessed using a 4 
point scale: 0 = no lameness; 1 = stiffness in some joints; 2 = mild lameness, slight limp visible; 
3 = moderate lameness, obvious limp that includes toe-touching; 4 = severe lameness, non-
weight bearing, needs encouragement to ambulate.  Fecal consistency scores were assigned using 
a 5 point scale: 0 = no feces; 1 = normal feces; 2 = soft but formed feces; 3 = brown diarrhea 
with particulate fecal material; 4 = brown diarrhea without particulate fecal material; 5 = clear, 
watery diarrhea.  Open mouth breathing, coughing, rhinorrhea, aural cyanosis, pallor or jaundice, 
muscle wasting, and joint effusion were described as: yes = present or no = absent.  Rectal 
temperature was only measured in pigs showing other visual signs of disease; as such, this 
parameter cannot be considered a stand-alone phenotype and has been excluded from the current 
report.  
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Appropriate veterinary treatments were initiated for pigs that presented with moderate to 
severe clinical disease.  Examples of clinical presentations where treatment was administered 
included: 1. Difficult respiration, 2. Mucoid nasal discharge, 3. Lameness with associated joint 
effusion, 4. Pallor or jaundice associated with muscle wasting, and 5. Lethargy or depression 
with rectal temperature ≥104°F.  For clinically affected pigs, antibiotic therapy was 
administered, including ceftiofur hydrochloride for respiratory or systemic disease, 
oxytetracycline for infectious arthritis, and enrofloxacin for cases refractory to the previous two 
antibiotics.  All pigs with overt clinical disease and rectal temperatures ≥104°F were 
administered flunixin meglumine, a nonsteroidal anti-inflammatory drug (NSAID).  Pigs with 
intractable fevers of greater than 4 days duration were given a 2 day wash-out period and then 
administered oral meloxicam.  All treatments were administered as directed by a veterinarian.  
For the purpose of recording veterinary treatment as a clinical phenotype, each day was 
described as: yes = treatment was administered or no = treatment was not administered.    
Clinical signs and systemic treatments unrelated to PRRSV or PCV2 (e.g. lacerations, 
dermatitis, hoof wounds, congenital hernias) were documented but were not included in the data 
analysis related to clinical phenotypes.  Animals were humanely euthanized with pentobarbital 
sodium if moribund or unresponsive to treatment.  Pigs that died or were humanely euthanized 
due to circumstances unrelated to the effects of co-infection (e.g. gastric torsion, musculoskeletal 
injuries, etc.) were excluded from the mortality analysis.  Average daily gain (ADG) was 
calculated as the change in weight divided by the number of days and was reported in kg. 
Measurement of PRRSV and PCV2 viremia. Viral DNA and RNA were extracted 
simultaneously from 50 μL of serum using Ambion’s MagMAX 96 Viral Isolation Kit (Applied 
Biosystems) in accordance to the manufacturer’s instructions.  PRRS viral RNA was quantified 
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using EZ-PRRSV MPX 4.0 Real Time RT-PCR Target-Specific Reagents (Tetracore) according 
to the manufacturer’s instructions.  For consistency, each plate contained Tetracore 
Quantification Standards and Control Sets for use with EZ-PRRSV MPX 4.0 RT-PCR Reagents.  
All PCR reactions were carried out on a CFX96 Touch Real-Time PCR Detection System (Bio-
Rad) in a 96-well format using the recommended cycling parameters.  PCV2 DNA was 
quantified using SsoAdvanced Universal SYBR Green Supermix (Bio-Rad).  Forward and 
reverse PCR primers were 5’-AATGCAGAGGCGTGATTGGA-3’ and 5’-
CCAGTATGTGGTTTCCGGGT-3’, respectively.  Primers were used at a final concentration of 
300 μM.  Nuclease free water was used to bring the mastermix volume to 18 μL per reaction.  
The addition of 2 μL of template nucleic acid brought the final reaction volume for each sample 
to 20 μL.  Standard curves and positive and negative controls were included on each plate.  
Plasmid DNA was used for the PCV2 standard curve and positive control template.  DNA 
inserted into the plasmid was obtained from a field strain of PCV2 (PCV2b 321/393).  Plasmid 
DNA was isolated using the PureYield Plasmid Miniprep System (Promega) according to the 
manufacturer’s instructions.  The DNA for the standard curve was quantified using a NanoDrop 
8000 Spectrophotometer.  The standard curve was produced by diluting the purified plasmid 
DNA 1:1000 in nuclease free water followed by five serial 1:10 dilutions in nuclease free water.  
The final standard curve contained 6 points ranging from 10
7
 to 10
2
 logs of template DNA which 
produced threshold crossing values between 15 and 33 cycles.  Standard curves were run in 
duplicate with nuclease free water as a negative control.  The PCV2 PCR was carried out on a 
CFX96 Touch Real-Time PCR Detection System using the following settings: activation at 98°C 
for 2 minutes, followed by 40 cycles of denaturing at 98°C for 5 seconds and 
annealing/extension at 60°C for 10 seconds.  The melting curve was performed between 65-95°C 
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using 0.5°C increments.  The PCR assay results were reported as log10 PRRSV RNA starting 
quantity (copy number) per 50 μL reaction volume or log10 PCV2 DNA starting quantity per 20 
μL reaction volume. 
Statistical analyses. Mortality was compared in the first half (0-20 dpi) and second half 
(21-42 dpi) of the post-challenge period using Fisher’s exact test with odds ratio reported.  
Clinical phenotypes in pigs that died compared to pigs that survived were also compared using 
Fisher’s exact test.  Mortalities were excluded from statistical analyses involving ADG and only 
those pigs surviving the 42 day post-challenge period were analyzed.  ADG comparisons for 
each clinical phenotype (presence or absence) were analyzed using the unpaired t-test.  Linear 
regression analysis was completed using days with each clinical phenotype as the predictor 
variable (x axis) and the ADG over 0-42 dpi as the response variable (y axis).  Linear regression 
was used to determine slope and significance of the relationship between the two variables.  
Pearson correlation coefficients (r) are reported for each linear regression analysis.  All analyses 
were performed using the GraphPad Prism 6.00 software.   
  
 Results 
PRRSV and PCV2 Viremia. The results for PRRSV and PCV2 viremia are shown for 
285 pigs in Figure 1.  On the day of challenge, 28% of pigs (77/276) had detectable PRRSV in 
the serum, consistent with the PRRS MLV vaccine administered 28 days prior to challenge.  At 
this time, low but detectable levels of the vaccine virus were detectable (mean = 0.67 log10 
templates per PCR reaction).  Throughout the post-challenge period, PRRSV infection followed 
the typical course, with replication peaking at between 4 and 11 dpi, followed by rapid decay and 
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virtual disappearance by 35 dpi, when 72.5% of pigs (177/244) had no detectable PRRSV in the 
serum.    
On the day of challenge, only 3% of pigs (9/276) had detectable levels of PCV2, a virus 
typically found in the environment.  Throughout the post-challenge period, PCV2 replication 
gradually increased until peak viremia at 21 dpi.  Between 21-42 dpi, large amounts of PCV2 
were maintained in the serum of most pigs.  At the conclusion of the study, PCV2 was still 
detected at an average of 3.0 log10 templates per PCR reaction and 27.5% of pigs (68/247) had 
greater than 4 log10 templates per PCR reaction.  Taken together, this data shows two different 
virus replication patterns, with the first half of the study characterized by PRRSV replication and 
the second half of the study characterized by PCV2 replication. 
Clinical Phenotypes. For the purpose of reporting clinical phenotypes in the current 
study, all of the scored clinical parameters were simplified into: yes = present or no = absent.  
For body condition, a score of < 3 was considered decreased (yes) and a score of ≥ 3 was 
considered normal (no).  For dyspnea, a score of ≥1 was considered present.  For lameness, a 
score of ≥ 1 was considered present.  For lethargy or depression, a score of ≥ 1 was considered 
present.  For diarrhea, a score of ≥ 2 was considered present. 
Table 2 summarizes the 13 clinical phenotypes measured in the 433 pigs that survived the 
42 day post-challenge period.  Clinical signs consistent with PRRSV or PCVAD were not 
present prior to challenge.  Phenotypes are listed in order of prevalence, with veterinary 
treatment administration, used as an overall measurement of morbidity, recorded in the greatest 
percentage of pigs (16.6%).  The remaining phenotypes provide more detailed information on 
clinical disease and were categorized into high, moderate or low prevalence.  High prevalence 
included dyspnea (12.0%), aural cyanosis (11.3%) and lethargy or depression (9.5%).  Moderate 
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prevalence included rhinorrhea (8.5%), coughing (8.1%), lameness (7.6%) and decreased body 
condition (5.8%).  Low prevalence phenotypes included clinical signs that occurred in less than 
5% of pigs.  These included jaundice or pallor (3.9%), diarrhea (3.5%), joint effusion (3.0%), 
open mouth breathing (2.5%) and muscle wasting (2.3%).   
The time course of clinical phenotypes over the 42 day post-challenge period is 
summarized in Figure 2.  Each day post-challenge was considered a separate data point; thus, the 
clinical phenotypes documented are representative of all pigs surviving on that day.  Therefore, it 
is important to consider that the reduction in clinical signs at approximately 34 dpi was due to 
the increase in mortality or euthanization of pigs that were moribund or nonresponsive to 
treatment (see Figure 4).  Clinical phenotypes were organized into four categories: A. 
nonspecific clinical phenotypes; B. porcine respiratory disease complex; C. phenotypes 
associated with PRRSV; and D. phenotypes associated with PCV2.     
Other than aural cyanosis, all clinical phenotypes primarily occurred in the second half of 
the post-infection period, which corresponded to high levels of PCV2 replication as well as an 
increase in mortality (see Figures 1 and 4).  Aural cyanosis is commonly known as “blue ear” 
(Done and Paton, 1995; Paton et al., 1991) and a representative image is shown in Figure 3A.  
The peak in aural cyanosis occurred between 9 and 14 dpi, corresponding to the peak in PRRSV 
viremia (see Figure 1).  Veterinary treatment, dyspnea and rhinorrhea have similar biphasic 
peaks, occurring between 20-24 dpi and 30-38 dpi.  Several phenotypes, such as coughing, open 
mouth breathing and diarrhea, failed to peak during the course of infection; these phenotypes 
never affected more than 2% of the population at any one time point.  Decreased body condition, 
lethargy or depression, muscle wasting and pallor or jaundice all peaked late in the post-infection 
period on either 33 or 34 dpi.  This peak is during high levels of PCV2 replication (see Figure 1) 
96 
and these clinical phenotypes are consistent with PCVAD.  A representative image of pallor is 
shown in Figure 3B.  Lameness and joint effusion peaked simultaneously between 34-42 dpi.  
Although lameness and joint effusion are not directly caused by PRRSV, these clinical signs are 
typically associated with PRRSV-induced immunosuppression.  
Mortality. During the 42 day study, 43 pigs died or were euthanized (43/476; 9.0%) due 
to clinical disease associated with PRRSV or PCV2 infections.  As illustrated in Figure 4, the 
majority of deaths occurred in the second half of the post-challenge period; 79% (34/43) between 
21-42 dpi compared to 21% (9/43) between 0-20 dpi.  Pigs were 4.0 times (95% CI [1.9, 8.4]) 
more likely to die between 21-42 dpi than 0-20 dpi (p = 0.0001, Fisher’s exact test).  This 
increase in mortality rate correlated with high levels of PCV2 and the peak in PCVAD.    
As expected, clinical phenotypes in the mortalities occurred at a much higher rate than 
the overall population.  For example, almost all mortalities were treated by a veterinarian (41/43; 
95.3%) and were documented to have lethargy or depression (37/43; 86.0%) and dyspnea (33/43; 
76.7%).  Other clinical phenotypes documented in the mortalities included decreased body 
condition (29/43; 67.4%), rhinorrhea (24/43; 55.8%), pallor or jaundice (19/43; 44.2%), 
coughing (15/43; 34.9%), open mouth breathing (14/43; 32.6%) and muscle wasting (11/43; 
25.6%).  The clinical phenotypes that occurred in the lowest proportion of mortalities were also 
shown to have the weakest associations with ADG (see below); aural cyanosis (7/43; 16.3%), 
lameness (8/43; 18.6%), joint effusion (3/43; 7.0%) and diarrhea (10/43; 23.3%).   
Mortality rates for pigs that were documented with each clinical phenotype are shown in 
Figure 5.  The highest mortality rates were documented in pigs with open mouth breathing 
(56.0%), decreased body condition (53.7%), jaundice or pallor (52.8%), and muscle wasting 
(52.4%).  The lowest mortality rates were documented in pigs with aural cyanosis (12.5%), joint 
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effusion (18.8%) and lameness (19.5%).  Almost all clinical phenotypes were more likely to be 
present in a pig that died compared to a pig that survived the 42 day post-infection period (p < 
0.0001, Fisher’s exact test).  For example, a pig that died was 18.5 times (95% CI [7.7, 44.4]) 
more likely to develop open mouth breathing than a pig that survived.  Lameness was more 
prevalent in the mortalities but at a lower statistical significance (p = 0.02, Fisher’s exact test).  
Two clinical phenotypes did not have significantly higher rates in the pigs that died; joint 
effusion and aural cyanosis (p = 0.17 and p = 0.32, respectively; Fisher’s exact test). 
Effect of Clinical Disease on Growth.  The distribution of average daily gain (ADG) 
from 0-42 dpi for all surviving pigs (n = 433) is shown in Figure 6.  Mean ADG for the whole 
group was 0.80 ± 0.20 kg and values ranged from 0.14 kg to 1.18 kg.  The ADG of pigs with 
clinical signs of PCVAD, including pallor or jaundice and/or muscle wasting, are highlighted in 
black on the distribution plot (see Figure 6).  Mean ADG for these pigs was 0.38 ± 0.15 kg and 
values ranged from 0.14 kg to 0.69 kg.  This data demonstrates how ADG is skewed to the left 
for pigs with these PCVAD phenotypes.   
ADG comparisons between pigs with and without each clinical phenotype are shown in 
Figure 7 and listed in Table 2.  The presence of muscle wasting, decreased body condition, and 
jaundice or pallor was associated with the greatest reductions in ADG; 62%, 56%, and 54% 
reductions, respectively (p < 0.0001; unpaired t-test).  Respiratory phenotypes were also 
associated with significant reductions in ADG, including coughing (43%), rhinorrhea (43%), 
open mouth breathing (40%) and dyspnea (34%).  Only the presence of two clinical phenotypes 
did not have significant associations with reducing ADG; lameness and aural cyanosis (p = 0.66 
and p = 0.18, respectively; unpaired t-test). 
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Linear regression analysis was performed between the number of days with each clinical 
phenotype and ADG from 0-42 dpi.  Table 2 summarizes the data from the linear regression 
analyses on all 13 clinical phenotypes and eight representative plots are shown in Figure 8.  The 
duration of veterinary treatment had a moderate to moderately low association with reducing 
ADG (r = -0.36) due to high levels of variability around the regression line (see Figure 8A).  As 
veterinary treatment is administered for a broad range of clinical signs, the remaining clinical 
phenotypes provide more detailed insight into the effects of clinical disease duration on ADG.  
For example, the duration of dyspnea had the strongest negative association with ADG (r = -
0.51), as demonstrated by a consistent decrease in ADG as duration of dyspnea progressed (see 
Figure 8B).  Open mouth breathing and muscle wasting have steep regression lines, with slopes 
equaling -0.227 kg and -0.193 kg, respectively.  This relationship is visually apparent in Figures 
8C and 8D, where the regression line estimates the ADG to equal zero at approximately 4 days 
duration.  However, the correlation coefficients are -0.25 and -0.32 for open mouth breathing and 
muscle wasting, respectively.  This moderately low association is likely due to the small number 
of pigs that had these clinical phenotypes (n = 11 and n = 10, respectively).  Jaundice or pallor 
and rhinorrhea had moderate associations with reducing ADG (r = -0.38 for both) and 
moderately steep regression lines (-0.063 kg and -0.059 kg, respectively; see Figures 8E and 8F).  
Similar associations were found for lethargy or depression, coughing, and decreased body 
condition (plots not shown).  The duration of diarrhea had a weak association with reducing 
ADG (r = -0.16) and a gradual regression line (-0.022 kg, plot not shown).  The duration of joint 
effusion, lameness and aural cyanosis had no significant associations with reducing ADG; this is 
demonstrated for the latter two phenotypes by the horizontal regression lines and evidence of 
prolonged clinical duration coupled with high ADG (see Figures 8G and 8H).       
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 Discussion 
Early identification of nursery pigs that have a high likelihood of poor growth 
performance or mortality is important to maintaining productivity and long-term economic 
viability in the swine industry.  Clinical disease can be used for early recognition of these poor 
performing pigs through keen observations and well-trained staff.  The prevalence of clinical 
disease is affected by several factors, including but not limited to host genetics, pathogen load, 
environmental conditions, vaccination, and immunity.  Co-infection of nursery pigs with two 
common swine pathogens, PCV2 and PRRSV, was used in these trials to model a polymicrobial 
disease syndrome and investigate the role of host genetics in determining outcome.  In each trial, 
large populations of co-infected pigs provided a unique opportunity to detail the broad range of 
clinical outcomes that occur after co-infection and investigate how clinical disease impacts 
growth and animal welfare.     
Over the course of 3 trials involving close to 500 pigs, thirteen clinical phenotypes were 
documented.  Historically, clinical signs have been difficult to measure in challenge experiments 
involving PRRSV or PCV2; precluding the collecting of significant data are low numbers of 
infected pigs combined with only a subpopulation of these pigs developing clinical disease.  
Large populations were necessary to mimic field conditions, where only 2-25% of pigs develop 
clinical disease during acute outbreaks of PCVAD (Kyriakis et al., 2002; Quintana et al., 2001; 
Sorden et al., 1998).  In the current study, only 1 out of every 4 pigs showed significant clinical 
disease (115/476; 24.2%), demonstrating the depth of data necessary to observe and quantify 
low-percentage clinical outcomes.  
Of 13 clinical phenotypes, aural cyanosis was the only one to peak in the first half of the 
post infection period.  Aural cyanosis is not pathopneumonic for PRRS; however, it often 
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coincides with acute PRRSV infection (Done and Paton, 1995; Paton et al., 1991) and is 
prevented by PRRS vaccination (Niederwerder et al., 2015).  In this study, the peak in aural 
cyanosis corresponded to the peak in PRRSV viremia at approximately 11 dpi.  Aural cyanosis 
was one of only two clinical phenotypes to lack a significant association with growth 
performance.  In early descriptions of PRRS, this lack of correlation between skin discoloration 
and other clinical signs was also recognized (Done and Paton, 1995).  However, this finding is in 
opposition to more recent reports on highly pathogenic PRRSV infections in China, where aural 
cyanosis coincides with severe disease (Zhou et al., 2008).  Thus, it is important to consider 
differences in strain virulence when determining the severity of aural cyanosis as a clinical 
phenotype.  Aural cyanosis is an easily identifiable clinical sign with low evaluator subjectivity.  
Due to its close relationship with the peak in PRRSV replication shown here and previously 
(Niederwerder et al., 2015), aural cyanosis may be useful in early recognition of a PRRS 
outbreak.  For example, an increased prevalence of aural cyanosis may indicate a PRRSV 
introduction or an emerging PRRSV isolate.  Although the presence and duration of aural 
cyanosis did not correlate with growth, monitoring changes in aural cyanosis over time may 
provide valuable information on the epidemiological trends of PRRS in a herd. 
Both PRRSV and PCV2 are common contributors to porcine respiratory disease complex 
or PRDC (Brockmeier, 2002).  Several phenotypes consistent with PRDC were documented in 
this study, including dyspnea, open mouth breathing, rhinorrhea, and coughing.  Dyspnea and 
rhinorrhea had similar biphasic peaks, while coughing and open mouth breathing failed to peak 
at any time point.  Similarly, two primary peaks in clinical disease were seen in field conditions, 
where weaned pigs were naturally exposed to both PCV2 and PRRSV (Martelli et al., 2013).  
This time course is likely due to associations with both PRRSV and PCV2 replication patterns 
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(see Figure 1).  Dyspnea leading to open mouth breathing had a strong association with reducing 
ADG.  Open mouth breathing is a severe sign of acute distress and compromised welfare in 
swine.  Measuring this clinical phenotype has been used to assess welfare during gas euthanasia 
(Sadler et al., 2014) and is commonly used to assess stress associated with transportation 
(Kephart et al., 2010; Pilcher et al., 2011; Ritter et al., 2007; Ritter et al., 2008).  In the current 
study, open mouth breathing was relatively rare but was associated with the highest mortality 
rate; of the 25 pigs that developed open mouth breathing, 14 pigs died (56% mortality).  With 
regards to recognition, open mouth breathing is arguably the least subjective clinical phenotype; 
therefore, it may be a model parameter to measure and implement into population monitoring 
records.  For a single day of open mouth breathing, there was an average reduction in ADG by 
0.227 kg.  When taken over the course of the 42 day study, this equates to 9.5 kg or 21.0 lbs in 
lost weight gain.  This would be a devastating loss to nursery pigs, in which the average exit 
weight in 2012 was 50.7 ± 8.4 lbs (Stalder, 2013).  Reducing the prevalence of open mouth 
breathing in nursery pig populations would decrease mortality, improve animal welfare, and 
increase growth.     
Although lameness and joint effusion are not directly caused by PRRSV infection, septic 
polyarthritis can be indirectly associated with PRRS-induced immunosuppression, increasing 
susceptibility to bacterial infections known to affect the joints, such as Mycoplasma hyosynoviae 
and Streptococcus suis (Galina et al., 1994; McOrist, 2014; Thanawongnuwech et al., 2000).  For 
example, pigs co-challenged with PRRSV and S. suis had a significantly higher incidence of 
arthritis compared to those pigs challenged with PRRSV or S. suis alone (Thanawongnuwech et 
al., 2000).  In the current study, lameness and joint effusion peaked late in the post-challenge 
period and were not associated with the peak in PRRSV replication.  This may be due to the 
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long-term effects of PRRS-induced immunosuppression.  Evidence of polyarthritis was seen at a 
similar rate to that reported for natural PRRSV infections; 8.8% in the current study (42/476) and 
15% in the field (Done et al., 1996).  Interestingly, the duration of lameness and joint effusion 
were not associated with significant reductions in ADG, and thus may not represent a significant 
factor in productivity losses due to clinical disease.   
Phenotypes associated with PCVAD, such as decreased body condition, lethargy or 
depression, muscle wasting and pallor or jaundice, all peaked late in the post-infection period 
during levels of high PCV2 replication.  Although diarrhea can be a sign of PCV2 enteritis 
(Segales, 2012), diarrhea was likely not associated with PCVAD in this study due to a lack of 
increased prevalence during PCV2 replication.  Diarrhea occurred in a low but relatively 
consistent percentage of pigs throughout the study period, failing to peak at any time point.  
Muscle wasting and reduced body condition are typical of PCV2-systemic infections, where pigs 
can lose extensive muscle mass and become emaciated.  However, growth retardation can also 
occur in pigs persistently infected with PRRSV, which likely contributed to decreased body 
condition scores late in the post-infection period.  Jaundice or pallor are also commonly reported 
in cases of PCVAD and are associated with gastric ulceration or granulomatous hepatitis 
resulting in hepatocellular necrosis (Opriessnig and Langohr, 2013; Quintana et al., 2001). 
Because of the ability for several diseases to cause decreased body condition and 
lethargy, jaundice or pallor and muscle wasting may be more specific for monitoring outbreaks 
of PCVAD.  Jaundice or pallor and muscle wasting were associated with significant reductions 
in ADG (see Figure 6) and high rates of mortality; 52.8% and 52.4%, respectively.  However, 
these mortality rates are lower than reports in the field during outbreaks of PCVAD, where case 
fatality rates can reach approximately 80% (Harding, 1997; Quintana et al., 2001).  Large 
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amounts of PCV2 were circulating in the serum of pigs that developed jaundice or pallor and/or 
muscle wasting.  On 7, 11, 14, 21, 28, 35 and42 dpi, PCV2 viremia levels were significantly 
greater in these pigs compared to the rest of the population (p < 0.02, unpaired t-test).  The 
greatest difference between the two groups was evident on 14 dpi, where mean PCV2 levels 
were 4.6 log10 templates/PCR reaction and 2.5 log10 templates/PCR reaction for pigs with and 
without these two clinical phenotypes, respectively (p < 0.0001, unpaired t-test).  As new isolates 
of PCV2 emerge, potentially resulting in outbreaks due to incomplete vaccine protection, 
integrating a herd monitoring plan for jaundice or pallor and muscle wasting may serve to 
improve early detection and response to PCVAD. 
Key performance indicators in swine production include measurements such as percent 
post-weaning mortality and time to market weight.  Ultimately, these indices are somewhat 
limited in their ability to detect disease early and prevent future loss.  Although it is widely 
accepted that clinical disease reduces growth, detailed clinical observations for individual pigs 
are typically considered impractical due to time and financial considerations as well as sheer 
volume in a production setting.  However, recently developed programs, such as Individual Pig 
Care (IPC; Zoetis), train swine husbandry personnel on early detection of clinical disease and 
administration of parenteral antimicrobial treatment to individual pigs.  This program emphasizes 
the individual, including electronic detailed daily observations and prompt treatment responses 
prior to progression of clinical disease (Azlor et al., 2013; Pantoja et al., 2013; Pineiro et al., 
2014).  In the current study, veterinary protocols were also directed at individualized evaluations 
and treatment; no group antimicrobials were administered in the water or feed.  Legal regulations 
limit the use of group administered antimicrobials, creating a need for early recognition of 
disease and targeted antibiotic administration.  Recognizing what clinical signs are most 
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predictive of poor growth and mortality provides an opportunity to eliminate antibiotic treatment 
for some clinical signs (i.e. aural cyanosis) and aggressively utilize antibiotics to treat others (i.e. 
open mouth breathing and muscle wasting).  Detailing clinical disease parameters as key 
performance indicators may help limit broad-scale antibiotic usage while demonstrating a 
commitment to improving animal welfare through improvements in clinical health.      
In conclusion, this report details clinical signs that occurred in a population of pigs after 
co-infection with PCV2 and PRRSV, two globally distributed viruses associated with severe 
economic losses to the swine industry.  Clinical phenotypes were diverse due to several 
polymicrobial syndromes and were shown to have associations with distress and compromised 
welfare, growth performance, and peak virus replication.      
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Table 3:1 Standardized health evaluation questionnaire* 
Attitude 0 1 2 3 4 
  Body Condition 1 2 3 4 5 
  Muscle Wasting No Yes 
     Pallor or Jaundice No Yes 
     Aural Cyanosis No Yes 
     Rectal Temperature 
       Lameness 0 1 2 3 4 
  
 
⁞Limb Affected LH RH LF RF 
   Joint Effusion No Yes 
     Dyspnea 0 1 2 3 4 5 6 
Open Mouth Breathing No Yes 
     Rhinorrhea No Yes 
     Coughing No Yes 
     Diarrhea 0 1 2 3 4 5 
 ‡Treatment Administration No  Yes     
 
    
*Clinical phenotypes associated with PRRSV/PCV2 co-infection assessed 
for presence and/or scored as described in the materials and methods 
‡Systemic treatment administered under the direction of a veterinarian; 
treatment protocols described in the materials and methods 
⁞Key: LH, Left hind; RH, Right hind; LF, Left front; RF, Right front 
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Table 3:2 Effect of presence and duration of clinical phenotype on average daily gain 
(ADG) from 0 to 42 days post-infection with PRRSV and PCV2 
 
  
Clinical Phenotype ADG‡ ADG Reduction† r valueǁ Slope⁞ Observations≡ 
Treatment 0.65 ± 0.27 22%* -0.36 -0.017* 72 
Dyspnea 0.55 ± 0.25 34%* -0.51 -0.042* 52 
Aural Cyanosis 0.76 ± 0.23 5% -0.04 -0.006 49 
Lethargy or Depression 0.50 ± 0.24 40%* -0.44 -0.043* 41 
Rhinorrhea 0.47 ± 0.20 43%* -0.38 -0.059* 37 
Coughing 0.47 ± 0.20 43%* -0.35 -0.072* 35 
Lameness 0.81 ± 0.23 0% +0.04 +0.003 33 
Decreased Body Condition 0.36 ± 0.13 56%* -0.41 -0.026* 25 
Jaundice or Pallor 0.37 ± 0.15 54%* -0.38 -0.063* 17 
Diarrhea 0.66 ± 0.31 17%* -0.16 -0.022* 15 
Joint Effusion 0.68 ± 0.31 15%* -0.02 -0.003 13 
Open Mouth Breathing 0.48 ± 0.20 40%* -0.25 -0.227* 11 
Muscle Wasting 0.31 ± 0.11 62%* -0.32 -0.193* 10 
‡ ADG shown in kg ± 1 standard deviation for pigs with each clinical phenotype 
† ADG reduction calculated for pigs with phenotype compared to pigs without phenotype; unpaired t-test 
ǁ Pearson correlation coefficient 
⁞ Slope calculated by linear regression analysis 
≡ Number of pigs with each clinical phenotype out of 433 surviving pigs 
* Statistical significance p < 0.05 
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Figure 3:1 Time course of viremia post-challenge with PRRSV and PCV2. 
Mean viremia is shown for PRRSV (dashed line) and PCV2 (solid line).  Data is shown for 285 
pigs. 
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Figure 3:2 Time course of clinical phenotypes after PRRSV/PCV2 challenge. 
Percent of pigs with each clinical phenotype is shown over the 42 day post-infection period for 
476 challenged pigs.  Phenotypes are categorized based on association with nonspecific disease 
(A.), porcine respiratory disease complex (B.), PRRSV infection (C.), or PCV2 infection (D.). 
116 
 
Figure 3:3 Examples of clinical phenotypes after PRRSV/PCV2 co-infection 
Aural cyanosis (A) and pallor (B) are shown.  A normal pig is included in the left side of each 
photo for the purposes of comparison. 
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Figure 3:4 Survival curve after challenge with PRRSV and PCV2. 
Percent of surviving pigs is shown for each day post-challenge.  Overall survival rate post 
challenge was 91% (433/476).  Approximately 21% (9/43) of the mortalities occurred in the first 
0-21 dpi; the remaining 79% (34/43) of the mortalities occurred in the second half of the post-
challenge period (21-42 dpi). 
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Figure 3:5 Mortality rates for pigs documented with each clinical phenotype after co-
infection with PRRSV and PCV2. 
Percent of pigs that died prior to the conclusion of the 42 day study period are shown for each 
clinical phenotype in descending order. 
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Figure 3:6 Distribution of average daily gain (ADG) from 0 to 42 days post-infection with 
PRRSV and PCV2. 
The ADG is shown for all surviving pigs (n = 433).  Pigs with clinical signs of porcine circovirus 
associated disease (PCVAD), including pallor or jaundice and/or muscle wasting, are shown in 
black (19/433; 4.4%).  Significant reductions in ADG were seen for each of these clinical 
phenotypes. 
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Figure 3:7 Reduction of ADG associated with the presence of each clinical phenotype. 
Data is shown as mean ADG in kg ± 1 standard deviation for pigs with one or more days of the 
clinical phenotype (black bars) and pigs without the clinical phenotype (grey bars).  Asterisks 
identify statistically significant differences between groups (**p < 0.0001, *p < 0.05; unpaired t-
test). 
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Figure 3:8 Linear regression plots showing association between days with each clinical 
phenotype and average daily gain (ADG). 
ADG is shown for each pig from 0-42 dpi (■) or until death (○). Linear regression line calculated 
for surviving pigs only (■).  Clinical phenotypes include A. Treatment, B. Dyspnea, C. Open 
Mouth Breathing, D. Muscle wasting, E. Jaundice or Pallor, F. Rhinorrhea, G. Lameness, and H. 
Aural Cyanosis.  
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Chapter 4 - Tissue localization, shedding, virus carriage, 
antibody response, and aerosol transmission of porcine 
epidemic diarrhea virus (PEDV) following inoculation of 4 
week-old feeder pigs 
 Abstract 
Porcine epidemic diarrhea virus (PEDV) emerged in the U.S. in April 2013 and caused 
significant losses to the swine industry.  The purpose of this investigation was to determine tissue 
localization, shedding patterns, virus carriage, antibody response, and aerosol transmission of 
PEDV following inoculation of 4 week-old feeder pigs.  Thirty-three pigs were randomly 
assigned to one of three groups for the 42 day study; challenge (Group A; n=23), contact 
transmission (Group B; n=5) and aerosol transmission (Group C; n=5).  Contact transmission 
occurred rapidly to Group B pigs whereas productive aerosol transmission failed to occur to 
Group C pigs.  Emesis was the first clinical sign noted at 3 days post-inoculation (DPI) followed 
by mild to moderate diarrhea lasting for an additional 5 days.  Real-time PCR detected PEDV in 
fecal and nasal swabs, oral fluids, serum, gastrointestinal and lymphoid tissues.  Shedding 
primarily occurred during the first 2 weeks post-challenge, peaking at between 5 and 6 DPI; 
however, some pigs had PEDV nucleic acid detected in swabs collected at 21 and 28 DPI.  
Antibody titers were measurable between 14 and 42 DPI.  Although feces and intestines 
collected at 42 DPI were PEDV negative by PCR and immunohistochemistry, respectively, small 
intestines from 70% of Group A pigs were PCR positive.  Although disease was relatively mild 
and transient in this age group, the results demonstrate that 4 week-old pigs are productively 
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infected and can sustain virus replication for several weeks.  Long-term shedding of PEDV in 
subclinical pigs should be considered an important source for PEDV transmission.     
  
 Introduction 
Porcine epidemic diarrhea (PED) emerged as a new swine enteric disease in North 
America in the spring of 2013 (Stevenson et al., 2013).  PEDV is an enveloped, positive-sense 
RNA virus in the family Coronaviridae (Jung and Saif, 2015).  Since initial detection, PEDV has 
spread rapidly across the U.S. and has now been reported in 34 states (American Association of 
Swine Veterinarians, http://www.aasv.org).  The mechanisms for introduction and rapid 
dissemination throughout pig farms in the U.S. and North America are still poorly understood; 
although, transportation, feed, and aerosols have all been implicated as potential contributors.  
The peak disease period for this virus is in the late fall and early winter months in temperate 
climates and clinical disease typically abates in the late spring, summer, and early fall.  Infection 
of neonatal pigs usually results in extremely high mortality (approaching 100%), due to 
malabsorptive diarrhea and dehydration as a result of enterocyte necrosis in the small intestine 
(Madson et al., 2015).  Infection of grow/finish animals results in high morbidity but low 
mortality with vomiting and mild to moderate diarrhea as the typical clinical presentation.  
Infection of adult swine is often overlooked due to minimal gastrointestinal signs or a complete 
lack of clinical disease.  Following the introduction of PEDV in the U.S., an estimated 7 million 
pigs died within the first year, placing pressure on domestic and foreign markets (Jung and Saif, 
2015).  Even though PEDV is very similar to the disease presentation caused by another 
coronavirus, transmissible gastroenteritis virus (TGEV), both viruses are genetically and 
immunologically distinct (Lin et al., 2015).   
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For the PEDV challenge in this study, 4 week-old pigs were selected as an intermediate 
age group, where clinical disease was expected to be mild to moderate and low mortality would 
allow the analysis of viral shedding, tissue distribution, aerosol transmission and antibody 
response over the 42-day period.  The results showed that clinical disease and associated 
pathology occur primarily within the first week after PEDV challenge, consistent with the 
outcome observed for similar-aged pigs in the field.  However, PEDV was still detected weeks 
after clinical signs had disappeared and may implicate pigs in this age group as an important 
source of viral carriage and transmission.    
  
 Materials and Methods 
Animals. Experiments involving animals and viruses were performed in accordance with 
the Federation of Animal Science Societies (FASS) Guide for the Care and Use of Agricultural 
Animals in Research and Teaching, the USDA Animal Welfare Act and Animal Welfare 
Regulations, and approved by the Kansas State University Institutional Animal Care and Use 
Committees and Institutional Biosafety Committees.  Thirty-three 3 week-old pigs were obtained 
from a high-health commercial source negative for PEDV.  All pigs were housed in one 
environmentally controlled room at the Biosecurity Research Institute at Kansas State 
University, and maintained under BSL3-Ag containment conditions.  The room was 
decontaminated with chlorine gas prior to the start of the study and was approximately 66 sq 
meters in size.  Pigs were housed in two raised stainless steel pens with slotted fiberglass 
flooring.  Pens were 6.9 and 3.5 sq meters in size for Groups A/B and Group C, respectively.  
The two pens were approximately 3 meters apart and were separated by a nonpermeable plastic 
tarp to avoid overt cross contamination while cleaning.  The tarp was placed directly between the 
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two pens and covered approximately 60% of the room length.  Pens were cleaned daily using a 
high heat and high pressure water hose.  Floors of the room were chemically disinfected daily 
with Virkon
 
(DuPont).  Pigs were given access to food and water ad libitum.  Complete exchange 
of air within the room occurred 14.5 times/hour.  Room temperature ranged from 73°F to 82°F 
and humidity ranged from 32% to 45% during the study.    
Experimental Design. Pigs were randomly assigned into one of three groups including a 
challenge group (Group A; n = 23), contact transmission group (Group B; n = 5) and aerosol 
transmission group (Group C; n = 5).  Experimental groups are summarized in Table 1.  The pigs 
were given one week to acclimate upon arrival.  At 4 weeks of age, Group A was inoculated with 
PEDV “feedback” inoculum via the oral and intranasal routes, with 5 ml of inoculum per route.  
The challenge material was a pool of gut-derived intestinal contents that had been used as 
“feedback” inoculum for controlled exposure of a sow herd in a commercial swine production 
unit.  The challenge material was kindly provided by Dr. Matt Ackerman of Swine Veterinary 
Services.  The PEDV inoculum (isolate USA/KS/2013, GenBank Accession #KJ184549.1) had a 
Ct of 22 as determined by the Kansas State Veterinary Diagnostic Laboratory (KSVDL) real-
time PCR assay.  This Ct value is equivalent to 1.42 x 10
5
 TCID50.  Routine diagnostic PCR 
testing by KSVDL showed the challenge inoculum was negative for porcine reproductive and 
respiratory syndrome virus (PRRSV), porcine circovirus (PCV), and group A, B and C 
rotaviruses. 
To inoculate Group A, pigs were individually removed from the group pen and 
administered the challenge material.  The Group B pigs were not inoculated and were housed 
separately from the Group A pigs during inoculation.  Approximately 6 hours post-inoculation of 
the Group A pigs, Groups A and B were allowed to co-mingle and were housed together for the 
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remainder of the study.  The Group C pigs were not inoculated and were housed in a separate 
pen in the same animal room as Groups A and B (described above).  Nasal swabs, fecal swabs, 
oral fluids, and serum samples were collected from all pigs prior to challenge on -3 and 0, 1, 2, 3, 
4, 5, 6, 7, 9, 14, 21, 28, 35, and 42 days post-inoculation (DPI).  One pig on 0, 2, and 4 DPI and 
two pigs on 7, 9, 14, 21, and 28 DPI were randomly selected for euthanasia and necropsy.  All 
remaining pigs were euthanized on 42 DPI.  To assess the presence of virus in the environment, 
swabs were collected from the V-troughs used for blood collection, walls, pens, and food bins 
from both the Group A/B and Group C sides of the room on 14 DPI.    
Clinical Evaluation. Pigs were evaluated daily throughout the study period for the 
presence of clinical signs associated with PED.  During the acute period of infection from 0-11 
DPI, each pig was physically examined by a veterinarian for clinical signs such as decreased 
body condition, dehydration, lethargy, and evidence of diarrhea or vomiting.  Lethargy was 
assessed through response to stimuli and interaction with pen mates.  Body condition scores 
(BCS) were assigned using an adapted 5 point scale (Patience and Thacker, 1989).  Dehydration 
was assessed through evaluation of enophthalmos and third eyelid protrusion, nasal planum 
moisture and coloration, mucus membrane moisture and coloration, and skin turgor.  Fecal 
consistency scores were assigned using a 5 point scale: 0 = no feces; 1 = normal feces; 2 = soft 
but formed feces; 3 = brown diarrhea with particulate fecal material; 4 = brown diarrhea without 
particulate fecal material; 5 = clear, watery diarrhea. 
Gross Anatomical and Histological Examination. Pigs were sequentially euthanized 
throughout the study to assess gross and microscopic changes during infection.  Pigs were 
euthanized with pentobarbital sodium, necropsied immediately and the following tissues were 
collected from each pig: inguinal lymph node, submandibular lymph node, tonsil, thymus, 
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thyroid gland, esophagus, trachea, lung (one section from each lobe), tracheobronchial lymph 
node, heart, liver, adrenal gland, kidney, spleen, stomach, mesenteric lymph node, duodenum 
with pancreas, jejunum (three locations), ileum, cecum, spiral colon (two locations), descending 
colon, nasal turbinates, bone marrow, and brain.  Tissues were frozen at -70°C and fixed in 10% 
neutral buffered formalin.  After 7 days, formalin-fixed tissues were routinely processed in an 
automated tissue processor, embedded in paraffin, tissue sections cut at 4 μm, mounted on glass 
slides, and stained with hematoxylin and eosin (H&E stain).  Necropsies and histologic 
evaluations of tissues were by a board-certified pathologist. 
PCR. The MagMAX-96 Viral RNA Isolation Kit
 
(Life Technologies) was used together 
with a Kingfisher 96 magnetic particle processor
 
(Fisher Scientific) for all sample types.  Tissue 
samples were homogenized using a Stomacher
®
 80 Biomaster
 
(ThermoScientific).  One milliliter 
of 1X PBS buffer was added to approximately 0.5 g of the feces or a nasal swab tube, vortexed 
briefly, and allowed to sit for 2-3 minutes.  The supernatant was then used for RNA extraction.  
For all sample types, 70 μl of liquid was used for RNA extraction.  The extracted RNA was 
frozen at -20°C until analysis by real-time reverse-transcription PCR (qRT-PCR).  
A duplex qRT-PCR was designed for the dual purpose of detecting PEDV nucleocapsid 
(N) protein gene and the host 18S ribosomal RNA subunit to monitor extraction efficiency.  
Primers and probe sequences for PEDV were: PEDVn-F2: GCT ATG CTC AGA TCG CCA GT, 
PEDVn-R2: TCT CGT AAG AGT CCG CTA GCT C, PEDVn-Pr2 probe: FAM-TGC TCT TTG 
GTG GTA ATG TGG C-BHQ1; Primers and probe sequences for 18S were: 18S-F: GGA GTA 
TGG TTG CAA AGC TGA, 18S-R: GGT GAG GTT TCC CGT GTT G, 18S-Pr probe: Cy5-
AAG GAA TTG ACG GAA GGG CA-BHQ2.  The Path-ID™ Multiplex One-Step Kit (Life 
Technologies) was used for all real-time PCR reactions.  The qRT-PCR reactions in 20 µL 
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consisted of 1.5 µL nuclease-free water, 10 µL 2X Reaction Buffer, 1 µL 10 µM PEDVn 
forward and reverse primers, 1 µL 10 µM 18S forward and reverse primers, 1 µL 10 µM 18S 
probe, 0.5 µL PEDV probe (10 µM), 1 µL Path-ID™ Multiplex One-Step Kit enzyme mix and 4 
µL extracted RNA.  Each qRT-PCR reaction plate was run on a Bio-Rad CFX96 Touch Real-
Time PCR Detection System
 
(Bio-Rad) under the following conditions: 48°C for 10 min; 95°C 
for 10 min; followed by 45 cycles of 95°C for 10 sec and 60°C for 40 sec.  Positive and negative 
PCR amplification controls and a negative extraction control were included in each run. 
Immunohistochemical (IHC) staining.  A primary goal for IHC staining was to 
determine if virus replication occurred in the respiratory tract as well as in the small intestine.  
Therefore, tissues from the gastrointestinal and respiratory tracts were prioritized for IHC 
staining after collection from pigs euthanized between 0 and 28 DPI.  Preliminary IHC 
examination of tissues for PEDV antigen was performed by Dr. Darin Madson at the Iowa State 
University Veterinary Diagnostic Laboratory.  Subsequently, Dr. Jerome Nietfeld performed 
IHC on these same tissues at the Kansas State Veterinary Diagnostic Laboratory (KSVDL), 
where positive and negative results were independently confirmed.      
Immunohistochemical staining at the KSVDL was performed on formalin-fixed paraffin-
embedded tissues that were sectioned at 4 μm thickness onto positively charged slides.  Slides 
were stained using the Bond-Max autostainer
 
(Leica Biosystems Inc.) with the Polymer Refine 
Detection kit (Leica Biosystems Inc.).  The PEDV primary antibody (SD 6-29, kindly provided 
by Dr. Eric Nelson) was diluted with Bond Primary Antibody Diluent
 
(Leica Biosystems Inc.) to 
1:100,000.  Epitope retrieval was performed by incubating slides in citrate pH 6.0 for 20 minutes 
at 100°C.  Tissue sections were incubated with the primary antibody for 15 minutes at ambient 
temperature.  Polymerization was performed with Powervision Poly-HRP α-Mouse Polymer 
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(Leica Biosystems Inc.) for 25 minutes at ambient temperature.  Visualization was done with 
DAB and counterstained with hematoxylin.  Positive and negative controls were included with 
each run. 
Antibody Response. Serum samples were collected throughout the study and stored at -
80
o
C for antibody testing using two methods.  First, serially diluted serum samples were assayed 
for PEDV antibodies using an indirect fluorescent antibody assay (IFA) in a 96-well format.  The 
IFA antigen was obtained by infecting swine testicular (ST) cells with a standardized stock of 
PEDV virus (Colorado 2013 Isolate, kindly provided by Dr. Sabrina Swenson).  IFA assay 
endpoints were calculated as the reciprocal of the last serum dilution that gave a positive IFA 
response when viewed with a fluorescent microscope. 
PEDV neutralizing antibody levels were determined using a 96-well microtiter system 
with African green monkey kidney (Vero) cells as the substrate and a standardized trypsin 
independent stock of PEDV as the indicator virus.  Serial dilutions of serum were mixed with a 
constant quantity of PEDV virus (50-300 TCID50), incubated for 1 hour at 37
o
C and inoculated 
into four replicate wells of 3-day old Vero cells in 96 well plates.  Cultures were incubated for 3 
days at 37
o
C and the presence of virus was determined by the presence of virus associated 
cytopathic effect.  Serum neutralization titers were based on 50% inhibition of the indicator virus 
and 50% endpoints were then determined by the method of Spearman and Karber (Finney, 
1964). 
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 Results 
Transmission. Group B pigs became rapidly infected with PEDV after co-mingling with 
Group A pigs.  In contrast, aerosol transmission did not occur as Group C pigs failed to develop 
a productive PEDV infection during the 42-day study period.  
Clinical Evaluation.  Clinical signs associated with PEDV infection were documented in 
Groups A and B between 3 and 8 DPI.  Figure 1 summarizes the time course of clinical disease 
in Group A pigs with the duration of PEDV detection in serum, fecal and nasal swabs, and small 
intestine.  Clinical disease correlated well with the time course of peak fecal and nasal PEDV 
shedding between 4 and 7 DPI (compare Figure 1 with Figures 3A and 3B).  The first clinical 
sign associated with PED was emesis noted on 3 DPI.  Vomitus contained partially digested food 
particulate and had no blood or mucus present.  The most severe diarrhea observed was assigned 
a score of 4/5 and included brown liquid feces without particulate fecal material, blood or mucus.  
This diarrheal score was recorded in 30% of the Group A and B pigs between 4 and 7 DPI.  
Evidence of clinical dehydration was documented in approximately 70% of Group A and B pigs 
between 4 and 8 DPI.  Dehydration was mild to moderate and resulted in pigs having 
enophthalmos with third eyelid protrusion, dry nasal planums, tacky mucus membranes, and 
decreased skin turgor.  During this time, most pigs also demonstrated evidence of mild to 
moderate lethargy, including a reluctance to rise and ambulate, decreased resistance to handling 
and restraint, and reduced responsiveness.  Starting on 4 DPI, the majority of pigs in Groups A 
and B (16/26; 61.5%) had body condition scores that were less than ideal (< 3/5).  However, 
body condition scores gradually improved after resolution of clinical disease and by 11 DPI, the 
majority of Group A and B pigs (13/21; 61.9%) had ideal body condition scores ( ≥ 3/5).  No 
pigs were considered moribund during the study and there were no mortalities. 
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Gross Anatomical, Histological and IHC Examination. Except for the mild to 
moderate dehydration observed clinically, gross lesions were not observed in any of the 
euthanized pigs.  All tissues collected from Group A pigs necropsied from 0 to 28 DPI were 
examined histologically and significant microscopic changes were present in the small intestines 
of 3 of 13 (23%) pigs.  There was diffuse, moderate to severe atrophy and fusion of villi in the 
jejunum and ileum of the pig necropsied on 4 DPI and in one of the two pigs necropsied on 7 
DPI.  Mild to moderate villous atrophy and fusion was present in the jejunum and ileum in one 
of the two pigs necropsied on 28 DPI.   
 Immunohistochemical staining results from Iowa State University and the KSVDL were 
identical.  PEDV was detected by IHC staining in the small intestines of six pigs (Table 2) and in 
the mesenteric lymph nodes of three pigs.  All five small intestinal samples from the pig 
euthanized at 4 DPI and in one of the two pigs euthanized at 7 DPI were positive.  One of five 
sections from both pigs euthanized at 14 DPI, and two of five sections from one of the two pigs 
euthanized at 21 and 28 DPI were positive.  In the pigs where all small intestinal sections were 
positive, PEDV antigen was multifocal in the villous epithelium of the duodenum and diffuse in 
the villous epithelium of the jejunum and ileum.  In pigs where only a portion of the sections 
were positive, viral antigen was limited to the jejunum and/or ileum and was absent from the 
duodenum.  In positive sections with Peyer’s patches, positive staining was often present within 
lymphoid tissue as well as the villous epithelium.  
Representative microscopic images of PEDV IHC in jejunal sections from Group A pigs 
are shown in Figure 2.  On 4 DPI, PEDV antigen was uniformly detected along the epithelial 
border, associated with villous atrophy and fusion (Figure 2A).  Between 7 and 28 DPI, PEDV 
antigen became less consistent along the epithelial border (Figures 2B-2E).  Taken together, this 
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data show a high degree of variability in IHC detection of PEDV antigen, particularly after 7 
DPI.   
PEDV Shedding and Viremia.  Real-time PCR results for PEDV in fecal and nasal 
swabs collected from all three groups are summarized in Figures 3A and 3B.  Individual animal 
results are shown in Tables 3 and 4.  In general, fecal and nasal shedding patterns were very 
similar between Group A and Group B pigs.  Surprisingly, all samples were negative for the 
virus at 24 hours post-inoculation.  Fecal and nasal shedding of Group A was first observed at 48 
hours post-inoculation.  Nasal shedding was detected in the Group B pigs at 48 hours post-
inoculation and fecal shedding was present in all five Group B pigs by 72 hours post-inoculation.  
Peak fecal shedding occurred between 5 and 6 DPI and was significantly greater than nasal 
shedding in both Groups A and B (compare Figures 3A and 3B).  Fecal shedding was typically 
detected at a 10 fold or greater level than that observed in the nares.  In Groups A and B, the 
majority of animals were negative for fecal and nasal shedding by 21 DPI.  However, three pigs 
in Group A (3/14; 21%) and two pigs in Group B (2/5; 40%) were still shedding virus in feces at 
21 DPI.  In addition, one pig from Group A (1/12; 8%) was shedding PEDV in feces and nasal 
secretions at 28 DPI.  Although low levels of PEDV nucleic acid were detected in all five Group 
C nasal swabs (5/5; 100%) during the early part of the study, the absence of fecal shedding and 
lack of antibodies suggested that the PEDV detected in nares was non-infectious.  
Mean PEDV viremia is shown in Figure 3C, and results for individual animals are listed 
in Table 5.  In general, the amount of PEDV nucleic acid was lower in serum compared to fecal 
and nasal samples.  Viremia peaked around 5 DPI, similar to fecal and nasal shedding.  PEDV 
viremia was clearly detected in the majority of both the Group A and B pigs.  Only three animals 
(3/25; 12%) in Groups A and B did not develop a detectable viremia within the first week post-
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challenge/exposure (see Table 5).  No detectable viremia was present in any of the samples from 
the Group C pigs (see Table 5C). 
Data on CT values for detection of PEDV shedding in oral fluids are shown in Figure 4.  
Viral nucleic acid was easily detected in oral fluids; levels were greater than nasal swabs but 
lower than levels detected in fecal swabs.  Oral fluids pooled from the pen housing Groups A and 
B were PCR positive at 2 DPI and remained positive until 28 DPI.  Oral fluids from Group C 
appeared to be positive at the time of the first successful collection point (4 DPI) and maintained 
positivity until 9 DPI.  Subsequent oral fluids collected from Group C were PEDV negative at 14 
DPI and a weak CT (>37) was observed on 21 and 28 DPI.   
Environmental PEDV.  Room environmental samples were collected at 14 DPI and the 
real-time PCR values are summarized in Figure 5.  The data show that viral nucleic acid was 
present on the V-troughs, pens and food bins on both the Group A/B and Group C sides of the 
animal room.  Differences between the two sides of the room were evident by the nucleic acid on 
the walls closest to the two pens; a CT value of 40.0 (negative) on the Group C wall and a CT 
value of 31.7 on the Group A/B wall.   
PEDV Tissue Tropism. Tissues tested for PEDV antigen by IHC over the course of the 
study are summarized in Table 6.  Of the tissues tested, only small intestines and mesenteric 
lymph nodes were positive on IHC.  All other tissues were IHC negative.  With regards to PEDV 
detection by PCR, the tissues tested and CT results are shown in Table 7.  Small amounts of viral 
nucleic acid were detected in several tissues in addition to small intestine and lymph node, 
including nasal turbinates, tonsil, thymus and spleen.   
Small intestinal sections and mesenteric lymph nodes from Group A pigs had the greatest 
amount of nucleic acid present between 4 and 7 DPI (see Table 7).  Most Group A pigs (7/10; 
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70%) maintained positive CT values in the small intestine until the end of the study at 42 DPI; 
whereas, all mesenteric lymph node samples had negative CT values at this time.  Interestingly, 
all Group B pigs had negative CT values in the small intestine at 42 DPI. 
Antibody Response.  Serological analysis of serum samples was performed using 
indirect fluorescent antibody (IFA) and serum neutralization assays.  Geometric mean titers for 
both assays are shown in Figure 6.  All pre-inoculation samples were negative for antibody and 
there was significant seroconversion in the Group A and B animals.  Seroconversion at 14 DPI in 
these groups correlates well with resolution of viremia (compare Figure 6 and Table 5).  There 
was no evidence of seroconversion in Group C, despite clear demonstration of PEDV nucleic 
acid in nasal and oral fluid samples.  Interestingly, the Group B animals reached lower peak 
antibody titers and appear to have more rapid antibody decay based on the IFA antibody test (see 
Figure 6A).  In addition, Group B animals reached peak neutralization titers 1 week after Group 
A at 21 DPI (see Figure 6B).   
 
 Discussion  
Porcine epidemic diarrhea virus (PEDV) emerged in the U.S. in April 2013 and had 
spread to most pork producing states within months, resulting in significant losses due to nursing 
piglet mortality.  PEDV pathogenesis is highly dependent on the age of the pig and in this study, 
we targeted 4 week-old feeder pigs to investigate transmission, antibody response, viral 
shedding, clinical outcome, and tissue tropism of PEDV over a 42 day period.  Four week-old 
pigs serve as an important age group due to the high potential for viral replication and shedding 
combined with the low potential for mortality.  As such, we were able to investigate the long 
term effects of PEDV infection.  This study showed that PEDV nucleic acid was present in the 
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small intestines of 4 week-old pigs for at least 42 days post-challenge, long after clinical disease 
had abated; thus, this age group may serve as an important source for chronic carriage and fecal 
transmission.   
Although PEDV is primarily transmitted through the fecal/oral route, viral transmission 
has also been associated with contaminated fomites such as trucks and personnel (Lowe et al., 
2014), contaminated feed ingredients (Bowman et al., 2015; Dee et al., 2014; Pasick et al., 
2014), and airborne virus particles (Alonso et al., 2014).  Alonso et al investigated the infectious 
potential for PEDV collected from air samples in both an experimental setting and a field setting 
with mixed results (Alonso et al., 2014).  In the experimental setting, PEDV was abundant in air 
samples collected from the room housing PEDV challenged pigs and was subsequently proven 
infectious in an 11 day-old pig bioassay.  In the field setting, PEDV was detected in 18% of air 
samples and up to 10 miles away from farms with acute outbreaks; however, quantities of PEDV 
were significantly lower than experimental conditions and productive infections did not occur in 
the 11 day-old pig bioassay (Alonso et al., 2014).  
Of the aforementioned modes of PEDV transmission, both contact and aerosol routes 
were investigated in the current study.  Rapid infection was clearly demonstrated in the Group B 
animals, with 4/5 pigs (80%) shedding PEDV in the feces 2 days after exposure to the Group A 
animals (see Table 3).  Transmission to Group B animals was likely due to fecal/oral direct 
contact with Group A animals; however, indirect contact with contaminated fomites, such as 
pens or food bins, cannot be eliminated.  Although viral shedding patterns and clinical signs 
were virtually identical between Groups A and B, two important differences should be 
highlighted.  First, most intestinal samples from Group A pigs (7/10; 70%) were PCR positive at 
42 DPI whereas none of the Group B intestinal samples (0/5; 0%) were positive at this time point 
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(p = 0.0256, Fisher’s exact test).  Second, antibody titers in the Group B pigs were typically 
lower and had more rapid decay when compared to Group A pigs.  These differences may be due 
to the Group B pigs being infected with a lower PEDV dose than Group A pigs, either through 
fecal/oral or environmental exposure, and may be better representative of field conditions.     
In contrast to contact transmission, productive aerosol transmission was not demonstrated 
in this study, despite repeated PEDV nucleic acid detection in the nares of all five of the aerosol 
transmission pigs.  There are several reasons the PEDV transmitted to the aerosol group may not 
have resulted in a productive infection.  First, the dose of PEDV transmitted via aerosolization 
may have been too low.  As shown in Table 4, the CT values detected in nasal swabs of the 
aerosol transmission pigs were relatively low, with the greatest quantity detected at a CT of 
31.45.  This may have been due to the small amount of virus aerosolization or may have been 
due to the BSL-3 housing conditions, where air exchange occurred almost 15 times each hour.  
Second, the circulating PEDV detected in nasal swabs may have been inactivated by chemicals 
used to disinfect the room.  Third, the lack of productive transmission may have been due to the 
number and age of the indicator animals.  For example, it is possible that this level of nucleic 
acid may have been infectious to highly susceptible 1 day-old neonatal piglets.  Future research 
is needed to understand the risk of airborne PEDV, the role of disinfectants in inactivating 
aerosolized particles, and the infectious dose necessary for productive aerosol transmission.       
Four week-old feeder pigs were selected for this challenge study due to the known 
reduction in PEDV mortality post-weaning, enabling us to monitor viral pathogenicity over the 
42 day study period.  Detection of PEDV nucleic acid in fecal swabs, nasal swabs, and oral fluids 
was relatively consistent between 2 and 14 DPI in this age group.  However, detection of PEDV 
viral antigen in intestinal sections was highly variable among pigs euthanized on the same day 
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post-challenge and inconsistencies were present within different intestinal sections collected 
from the same pig (see Table 2).  Of the pigs that were negative on IHC for PEDV antigen 
between 2 and 9 DPI, all pigs (4/4; 100%) were positive for PEDV nucleic acid in fecal swabs.  
Specifically, one of the pigs euthanized on 7 DPI was negative on IHC but was shedding large 
amounts of PEDV nucleic acid in the feces collected on the same day (CT = 21.52).  In addition, 
all pigs euthanized after 2 DPI had high levels of PEDV nucleic acid detected in small intestinal 
samples (Table 7).  Discrepancies between IHC and PCR results were also reported in 3 week-
old pigs after challenge with a different PEDV strain (Madson et al., 2014).  These IHC 
inconsistencies warrant collection of several intestinal sections from multiple pigs to ensure 
initial diagnosis and complete resolution of PEDV carriage after an acute outbreak.  Further, 
PCR may prove to be a more sensitive technique for diagnostic testing in weaned pigs.   
Mild to moderate clinical disease was documented for approximately 1 week after PEDV 
challenge in the Group A pigs.  However, PEDV shedding in fecal and nasal swabs were 
detected up to 28 DPI, approximately 3 weeks after clinical disease had abated.  In addition, 
PEDV nucleic acid was detected in intestinal samples from most Group A pigs (7/10:70%) at the 
conclusion of the study.  As 42 days was the study duration, it is unclear how long intestinal 
samples may have remained PCR positive after challenge.  This is concerning due to the 
possibility of long term virus carriage and shedding in an age group where transient and mild 
clinical signs could be easily overlooked in a large production system.  However, we do not 
know the infectious transmissibility of the PEDV detected in fecal swabs or intestinal samples.  
Moreover, each one of the seven pigs that tested positive for PEDV nucleic acid in the intestine 
at 42 DPI had negative fecal swabs collected on the same day, indicating the presence of 
intestinal PEDV with a lack of viral shedding.  It is possible that chronic viral presence in the 
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intestine does not pose a risk for transmission.  In view of these findings, Crawford et al 
investigated horizontal transmission of PEDV to naïve pigs in an experiment designed to mimic 
an endemic infection (Crawford et al., 2015).  In this study, naïve pigs were introduced at weekly 
intervals to a group of pigs naturally exposed to PEDV.  Although pigs exposed to PEDV had 
intermittent viral shedding through 42 DPI, naïve pigs only became infected when introduced at 
7 and 14 DPI, but not at later time points (Crawford et al., 2015).  These results again highlight 
the need for future research on understanding the minimum infectious dose for different age 
groups and differentiating between a positive PCR result and the presence of infectious virus.    
In summary, PEDV was transmitted rapidly via natural contact but was not transmitted 
via the aerosol route in this study, despite recurrent detection of nucleic acid in the nasal swabs 
of the aerosol transmission pigs.  Although the greatest amounts of virus were present in feces, 
PEDV was also detected in nasal swabs, oral fluids, and serum starting at 2 DPI.  Clinical disease 
in 4 week-old pigs was transient and primarily occurred in the first week post-challenge; 
however, PEDV was detected in these pigs up to 6 weeks post-challenge.  This study supports 
the notion that post-weaning pigs should be considered as possible reservoirs for PEDV 
transmission and may support subclinical infections long after resolution of clinical signs.   
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Table 4:1 Experimental design for PEDV challenge in 4 week-old feeder pigs 
Group Treatment n 
A PEDV inoculated* 23 
B None: Contact Transmission† 5 
C None: Aerosol Transmission‡ 5 
* Inoculation via oral and intranasal routes; 5 ml/route 
† Co-mingled with Group A 6 hours post-inoculation 
‡ Housed in a separate pen in the common animal room 
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Table 4:2 Immunohistochemistry summary of small intestinal sections collected 
sequentially from Group A pigs after challenge with PEDV* 
 
DPI Reactivity  Positive Sections (%) 
0 -  0 
2 - 0 
4 + 100 
7 + 100 
7 - 0 
9 - 0 
9 - 0 
14 + 20 
14 + 20 
21 + 40 
21 - 0 
28 + 40 
28 - 0 
*Pigs were randomly selected throughout the study for 
sequential collection.  Five sections of small intestine 
were collected from each pig and evaluated for the 
presence of PEDV antigen on immunohistochemistry. 
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Table 4:3 PEDV fecal shedding in individual animals until death or 42 DPI* 
    
Day Post-Inoculation (DPI) 
      Group -3 0 1 2 3 4 5 6 7 9 14 21 28 35 42 
A.  
40.0 40.0 40.0 36.0 37.2 21.4 21.7 25.7 25.9 30.1 23.9 40.0 40.0 40.0 40.0 
40.0 40.0 40.0 20.8 21.7 19.2 20.0 23.8 26.3 32.0 26.5 
    40.0 40.0 40.0 34.4 20.3 19.2 20.9 21.2 22.9 28.3 28.2 27.6 
   40.0 40.0 40.0 30.9 21.2 17.5 19.7 28.0 25.3 25.4 36.1 40.0 40.0 40.0 40.0 
40.0 40.0 40.0 34.8 
           40.0 40.0 40.0 37.3 36.6 21.9 19.9 19.6 21.5 26.9 32.8 
    40.0 40.0 40.0 38.2 36.9 25.3 22.4 22.7 22.2 32.8 26.5 40.0 40.0 40.0 40.0 
40.0 40.0 
             40.0 40.0 40.0 34.0 34.0 19.6 18.4 18.8 20.4 23.2 34.4 40.0 40.0 
  40.0 40.0 40.0 32.9 40.0 20.7 
         40.0 40.0 40.0 34.1 32.0 25.8 18.8 18.3 18.1 23.7 32.9 40.0 40.0 40.0 40.0 
40.0 40.0 40.0 32.2 32.2 24.7 21.2 20.0 22.2 
      40.0 40.0 40.0 40.0 40.0 22.1 20.9 21.0 21.1 29.2 26.1 40.0 24.5 
  40.0 40.0 40.0 37.0 35.4 20.2 20.1 18.5 19.0 26.0 34.5 40.0 40.0 40.0 40.0 
40.0 40.0 40.0 23.5 29.4 20.7 18.8 19.2 22.0 26.1 23.5 29.6 40.0 40.0 40.0 
40.0 40.0 40.0 34.7 34.7 25.4 19.6 17.4 16.9 22.1 40.0 40.0 40.0 40.0 40.0 
40.0 40.0 40.0 35.4 35.5 30.0 22.3 22.9 27.4 25.2 27.7 32.5 40.0 40.0 40.0 
40.0 40.0 40.0 34.5 36.2 25.9 19.1 21.9 21.1 32.8 28.3 40.0 40.0 40.0 40.0 
40.0 40.0 40.0 24.8 31.1 22.3 20.7 21.3 25.2 23.2 
     40.0 40.0 40.0 33.9 36.2 25.7 19.2 20.5 22.4 28.8 30.3 40.0 
   40.0 40.0 40.0 17.4 22.8 25.3 22.9 24.5 27.1 30.3 
     40.0 40.0 40.0 29.4 40.0 19.2 20.0 19.1 21.5 
      40.0 40.0 40.0 34.4 34.9 29.2 22.0 18.8 22.5 27.0 40.0 40.0 40.0 40.0 40.0 
B. 
40.0 40.0 40.0 35.3 36.8 23.4 19.6 20.6 24.2 31.7 36.8 40.0 40.0 40.0 40.0 
40.0 40.0 40.0 36.5 34.2 27.1 20.8 21.0 20.0 23.9 28.4 40.0 40.0 40.0 40.0 
40.0 40.0 40.0 39.4 36.4 28.5 19.1 21.7 22.2 24.1 40.0 37.0 40.0 40.0 40.0 
40.0 40.0 40.0 34.7 36.0 21.9 19.8 20.1 21.1 26.6 32.9 40.0 40.0 40.0 40.0 
40.0 40.0 40.0 36.1 19.9 35.4 22.7 19.2 22.3 22.9 32.3 29.6 40.0 40.0 40.0 
C.  
40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 39.5 40.0 40.0 40.0 40.0 40.0 40.0 
40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
*Cycle Threshold (CT) values are shown for animals within the inoculated (A.), contact transmission (B.) and 
aerosol transmission (C.) groups. Values are color-coded based on a numerical gradient with the lowest CT 
values being red and the greatest CT values being green.  A CT value of ≥38 was considered negative. 
145 
Table 4:4 PEDV nasal shedding in individual animals until death or 42 DPI* 
    
Day Post-Inoculation (DPI) 
      Group -3 0 1 2 3 4 5 6 7 9 14 21 28 35 42 
A.  
40.0 40.0 40.0 29.7 34.2 28.1 29.4 28.5 29.0 33.0 40.0 40.0 40.0 40.0 40.0 
40.0 40.0 40.0 29.8 37.1 31.4 31.5 29.2 28.9 32.6 36.6 
    40.0 40.0 40.0 31.3 34.2 30.8 30.4 30.0 30.4 29.9 35.9 35.7 
   40.0 40.0 40.0 26.9 30.6 27.7 28.9 27.0 28.7 31.0 35.2 36.8 40.0 40.0 40.0 
40.0 40.0 40.0 32.3 
           40.0 40.0 40.0 32.2 32.0 29.1 29.6 28.1 27.4 32.1 36.6 
    40.0 40.0 40.0 32.3 33.4 32.5 29.8 29.4 31.1 32.6 40.0 40.0 40.0 40.0 40.0 
40.0 40.0 
             40.0 40.0 40.0 32.0 31.1 29.0 30.0 29.3 28.9 29.8 36.0 38.4 40.0 
  40.0 40.0 40.0 29.1 33.0 30.6 
         40.0 40.0 40.0 28.8 30.1 24.5 27.4 26.1 28.2 29.7 35.3 40.0 40.0 40.0 40.0 
40.0 40.0 40.0 31.1 34.4 29.0 28.7 29.6 29.0 
      40.0 40.0 40.0 32.3 29.2 26.6 29.2 27.9 30.9 28.8 35.6 36.1 32.9 
  40.0 40.0 40.0 31.1 32.4 28.2 27.8 25.4 31.0 30.8 38.1 40.0 40.0 40.0 40.0 
40.0 40.0 40.0 33.5 31.3 28.0 29.8 28.4 31.0 29.0 35.8 38.1 40.0 40.0 40.0 
40.0 40.0 40.0 29.2 33.2 28.4 28.8 30.2 21.5 29.5 37.0 40.0 40.0 40.0 40.0 
40.0 40.0 40.0 29.5 32.4 28.9 27.8 29.6 30.7 30.3 
 
40.0 40.0 40.0 40.0 
40.0 40.0 40.0 30.4 33.2 30.2 28.9 26.6 31.9 28.2 36.4 39.9 39.9 40.0 40.0 
40.0 40.0 40.0 28.8 31.2 29.6 28.7 27.9 29.3 30.0 
     40.0 40.0 40.0 29.8 31.6 30.1 29.7 30.6 29.8 32.7 35.1 40.0 
   40.0 40.0 40.0 27.6 31.3 29.4 29.5 28.2 30.8 31.2 
     40.0 40.0 40.0 30.3 32.2 29.7 29.4 31.7 30.0 
      40.0 40.0 40.0 30.7 31.1 29.1 28.8 29.6 31.0 29.5 34.8 40.0 40.0 40.0 40.0 
B.  
40.0 40.0 40.0 30.3 33.0 30.4 30.0 27.3 27.5 30.9 35.3 40.0 40.0 40.0 40.0 
40.0 40.0 40.0 28.6 37.1 30.1 29.6 29.1 27.4 31.1 36.8 40.0 40.0 40.0 40.0 
40.0 40.0 40.0 29.2 32.2 29.7 29.5 30.2 31.8 32.8 36.8 40.0 40.0 40.0 40.0 
40.0 40.0 40.0 29.8 30.1 29.5 29.4 30.0 32.6 31.2 33.5 40.0 37.1 40.0 40.0 
40.0 40.0 40.0 33.3 31.3 22.2 29.6 27.7 28.1 29.6 38.4 37.1 40.0 40.0 40.0 
C. 
40.0 40.0 40.0 40.0 40.0 40.0 35.9 38.3 32.5 33.9 38.3 40.0 40.0 40.0 40.0 
40.0 40.0 40.0 37.2 40.0 36.7 37.2 37.0 36.5 40.0 40.0 40.0 40.0 40.0 40.0 
40.0 40.0 40.0 35.9 40.0 36.8 37.4 36.7 34.0 36.5 40.0 40.0 40.0 40.0 40.0 
40.0 40.0 40.0 35.4 37.9 40.0 37.2 36.7 33.4 34.6 40.0 40.0 40.0 37.9 40.0 
40.0 40.0 40.0 40.0 40.0 35.6 35.7 37.0 33.1 31.5 40.0 40.0 40.0 40.0 40.0 
*Cycle Threshold (CT) values are shown for animals within the inoculated (A.), contact transmission (B.) and 
aerosol transmission (C.) groups. Values are color-coded based on a numerical gradient with the lowest CT 
values being red and the greatest CT values being green.  A CT value of ≥38 was considered negative. 
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Table 4:5 PEDV viremia in individual animals until death or 42 DPI* 
   
Day Post-Inoculation (DPI)   
   Group 1 2 3 4 5 6 7 9 14 42 
A.  
40.0 40.0 40.0 40.0 36.2 35.8 40.0 40.0 40.0 40.0 
40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
 
40.0 40.0 30.0 31.0 30.5 29.8 32.5 37.4 40.0 
 
40.0 33.3 37.0 35.6 35.5 34.6 40.0 40.0 40.0 40.0 
40.0 40.0 
        
40.0 40.0 40.0 36.9 37.3 37.5 37.4 40.0 40.0 
 
40.0 40.0 33.7 34.5 40.0 40.0 40.0 40.0 40.0 40.0 
40.0 40.0 40.0 40.0 32.5 32.9 32.3 40.0 40.0 
 
40.0 40.0 36.9 36.7 
      
40.0 40.0 40.0 33.6 40.0 40.0 40.0 40.0 40.0 40.0 
40.0 40.0 30.8 37.5 37.3 36.3 40.0 
   
40.0 40.0 40.0 37.4 37.3 40.0 40.0 40.0 40.0 
 
40.0 40.0 34.6 31.6 29.9 29.5 30.0 40.0 40.0 40.0 
40.0 40.0 40.0 36.8 40.0 40.0 40.0 40.0 40.0 40.0 
40.0 40.0 35.4 36.0 40.0 40.0 40.0 40.0 40.0 40.0 
40.0 40.0 40.0 40.0 35.9 40.0 36.9 40.0 40.0 40.0 
40.0 40.0 40.0 36.0 33.7 38.3 40.0 40.0 40.0 40.0 
40.0 33.7 30.4 36.3 40.0 40.0 40.0 40.0 
  
40.0 40.0 40.0 36.9 40.0 40.0 40.0 40.0 40.0 
 
40.0 32.6 34.2 31.7 32.2 34.2 36.9 40.0 
  
40.0 40.0 38.1 40.0 40.0 40.0 40.0 
   
40.0 40.0 40.0 36.0 33.4 34.2 35.3 37.4 40.0 40.0 
B. 
40.0 40.0 35.4 31.5 32.4 33.1 33.2 39.3 40.0 40.0 
40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
40.0 40.0 32.4 34.2 34.6 37.3 37.2 40.0 40.0 40.0 
40.0 40.0 40.0 36.9 36.2 36.0 40.0 40.0 40.0 40.0 
40.0 40.0 40.0 40.0 36.6 36.3 36.6 37.3 40.0 40.0 
C. 
40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 
*Cycle Threshold (CT) values are shown for animals within the inoculated (A.), 
contact transmission (B.) and aerosol transmission (C.) groups. Values are color-
coded based on a numerical gradient with the lowest CT values being red and the 
greatest CT values being green.  A CT value of ≥38 was considered negative. 
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Table 4:6 Summary of tissues stained by the immunohistochemical method for PEDV* 
 Day Post-Inoculation 
Tissue 0 2 4 7 7 9 9 14 14 21 21 28 28 
Stomach KI
 
KI KI KI KI KI K KI KI KI K KI K 
Small intestines KI KI KI KI KI KI KI KI KI KI KI KI KI 
Large intestines KI KI KI KI KI KI KI KI KI KI KI KI KI 
Pancreas KI K KI KI KI KI K K KI KI KI K KI 
Turbinates K KI KI KI KI KI KI KI KI KI KI KI KI 
Trachea KI KI KI KI KI KI KI KI KI KI KI KI KI 
Lungs KI KI KI KI KI KI KI KI KI KI KI KI KI 
Lymph nodes KI K KI KI KI K KI KI KI K K KI K 
Tonsil K NP K K K K K K K K K K K 
Tongue - KI - KI - - - KI - K - K - 
Esophagus K KI - K KI KI KI KI KI K K KI K 
Thymus K K K K K K KI K K K - K - 
Thyroids KI K K KI - K K - KI - - - K 
Adrenals KI K - K - K K - - - - K - 
Bone marrow - - - - - - KI KI KI - - - - 
Liver KI - - KI KI KI - - - - - - - 
Kidney KI - - K - K - - - - - - - 
Spleen K K - K - K - - - - - - - 
Heart KI - K KI KI KI KK KI KI K - K - 
*Only small intestine and mesenteric lymph nodes were IHC positive 
K = IHC stained at Kansas State Veterinary Diagnostic Laboratory 
KI = IHC stained at Kansas State and Iowa State Veterinary Diagnostic Laboratories 
- = Tissue not stained 
NP = Tissue not processed  
  
148 
Table 4:7 Real-time PCR detection of PEDV in tissues collected sequentially throughout 
the study or at 42 DPI* 
 
Group DPI 
Nasal 
Turbinate Tonsil Trachea Lung 
Lymph 
Node Thymus Spleen 
Small 
Intestine 
 A.  
0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 39.9 
2 36.2 38.4 40.0 40.0 40.0 36.3 40.0 36.8 
4 40.0 35.3 40.0 39.1 27.7 40.0 40.0 13.6 
7 
39.7 36.6 40.0 40.0 23.3 39.9 36.7 14.5 
38.7 35.5 40.0 40.0 26.7 34.5 40.0 25.0 
9 
40.0 35.2 40.0 40.0 31.7 40.0 29.2 26.3 
40.0 40.0 40.0 40.0 33.5 38.3 33.5 27.8 
14 
40.0 38.9 40.0 40.0 30.7 40.0 38.2 22.0 
40.0 40.0 40.0 40.0 31.9 40.0 35.5 29.7 
21 
38.6 38.6 40.0 40.0 32.9 40.0 35.1 19.9 
40.0 40.0 40.0 40.0 35.3 40.0 37.3 28.2 
28 
40.0 40.0 40.0 40.0 30.1 40.0 38.3 27.5 
40.0 36.5 40.0 40.0 34.7 35.6 40.0 18.9 
 
A.  42 
  
   
40.0 
  
32.6 
  
   
40.0 
  
40.0 
  
   
40.0 
  
40.0 
  
   
40.0 
  
32.1 
  
   
40.0 
  
32.0 
  
   
40.0 
  
35.8 
  
   
38.8 
  
38.4 
  
   
40.0 
  
32.4 
  
   
40.0 
  
34.3 
        39.0     35.3 
B. 42 
        40.0     40.0 
  
   
40.0 
  
40.0 
  
   
40.0 
  
40.0 
  
   
40.0 
  
40.0 
        40.0     40.0 
C.  42 
  
   
40.0 
  
40.0 
  
   
40.0 
  
40.0 
  
   
40.0 
  
40.0 
  
   
40.0 
  
40.0 
        40.0     40.0 
*Cycle Threshold (CT) values are shown for inoculated (A.), contact transmission (B.) and aerosol 
transmission (C.) groups sequentially collected during the study or at 42 DPI. Values are color-
coded based on a numerical gradient with the lowest CT values being red and the greatest CT 
values being green.  A CT value of ≥38 was considered negative. 
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Figure 4:1 Time course of clinical disease and PEDV detection in Group A pigs after PEDV 
inoculation. 
Clinical disease was assessed as described in the materials and methods.  Clinical signs 
consistent with PEDV were not present after 10 DPI. 
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Figure 4:2 PEDV immunohistochemistry of jejunal sections from Group A pigs 
sequentially collected after PEDV challenge. 
 
Images are shown from tissues collected: A. 4 DPI; B. 7 DPI; C. 14 DPI; D. 21 DPI; and E. 28 
DPI. 
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Figure 4:3 PCR detection of PEDV in fecal swabs (A), nasal swabs (B) and serum (C) after 
PEDV inoculation. 
Data is represented by real-time PCR group mean cycle thresholds (CT) ± 1 standard deviation.  
Inoculated (▲), contact transmission (■) and aerosol transmission (○) groups are shown.  A CT 
value of ≥38 was considered negative. 
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Figure 4:4 PCR detection of PEDV in pooled oral fluid samples after PEDV challenge. 
Data is represented by real-time PCR cycle thresholds (CT).  Pen samples from Groups A and B 
(●) and Group C (○) are shown.  A CT value of ≥38 was considered negative. 
 
153 
 
Figure 4:5 PEDV detection in environmental samples collected on 14 DPI. 
Swabs were collected from both the Groups A and B side and the Group C side of the common 
animal room.  Data is represented by real-time PCR cycle thresholds (CT).  A CT value of ≥ 38 
was considered negative. 
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Figure 4:6 Antibody response after PEDV challenge in all 3 experimental groups. 
Data is represented by the group geometric mean indirect fluorescent antibody titer (A) and 
serum neutralization titer (B) during each week post-inoculation.  Inoculated (▲), contact 
transmission (■) and aerosol transmission (○) groups are shown.  A. Antibody titers < 40 
adjusted to 35 and B. Antibody titers of < 20 adjusted to 15 for improved visibility. 
 
 
 
 
 
